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ABSTRACT 
Liyun Cao 
MECHANISM OF TISSUE TRANSGLUTAMINASE UPREGULATION AND ITS ROLE 
IN OVARIAN CANCER METASTASIS 
Ovarian cancer (OC) is a lethal disease due to metastasis and 
chemoresistance. Our laboratory previously reported that tissue transglutaminase 
(TG2) is overexpressed in OC and enhances OC peritoneal metastasis. TG2 is a 
multifunctional protein which catalyzes Ca2+-dependent cross-linking of proteins. The 
purpose of this study was to explore the mechanism by which TG2 is upregulated in 
OC and its role in OC progression. We demonstrated that transforming growth factor 
(TGF)-β1 is secreted in the OC milieu and regulates the expression and function of 
TG2 primarily through the canonical Smad signaling pathway. Increased TG2 
expression level correlates with a mesenchymal phenotype of OC cells, suggesting 
that TGF-β1 induced TG2 promotes epithelial-to-mesenchymal transition (EMT). TG2 
induces EMT by negatively regulating E-cadherin expression. TG2 modulates E-
cadherin transcriptional suppressor Zeb1 expression by activating NF-κB complex, 
which leads to increased cell invasiveness in vitro and tumor metastasis in vivo. The 
N-terminal fibronectin (FN) binding domain of TG2 (tTG 1-140), lacking both 
enzymatic and GTPase function, induced EMT in OC cells, suggesting the interaction 
with FN involved in EMT induction. A TGF-β receptor kinase inhibitor, SD-208, 
blocked TGF-β1 induced TG2 upregulation and EMT in vitro and tumor dissemination 
in vivo, which confirms the link between TGF-β1 and TG2 in EMT and tumor 
metastasis. TG2 expression was correlated with the number and size of self-renewing 
 
 
vii 
spheroids, the percentage of CD44+CD117+ ovarian cancer stem cells (CSCs) and 
with the expression level of stem cell specific transcriptional factors Nanog, Oct3/4, 
and Sox2.  These data suggest that TG2 is an important player in the homeostasis of 
ovarian CSCs, which are critical for OC peritoneal metastasis and chemoresistance. 
TG2 expression was also increased in CSCs isolated from human ovarian tumors, 
confirming the implication of TG2 in CSCs homeostasis. Further, we demonstrated 
that TG2 protects OC cells from cisplatin-induced apoptosis by regulating NF-κB 
activity. We proposed a model whereby TGF-β-inducible TG2 modulates EMT, 
metastasis, CSC homeostasis and chemoresistance in OC. These findings contribute 
to a better understanding of the mechanisms of OC metastasis modulated by TG2. 
 
Daniela Matei, M.D., Chair 
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CHAPTER 1: INTRODUCTION  
1.1 Ovarian cancer (OC) 
There are three types of cells in the ovary, each with distinct origin and 
functions: epithelial cells, which cover the ovary; germ cells, which develop into 
eggs (ova) that are released into the fallopian tubes every month; and stromal 
cells, which form the supporting or structural tissue holding the ovary together 
and produce the female hormones, estrogen and progesterone. Accordingly, 
ovarian tumors can arise from each of these components, giving rise to epithelial 
ovarian cancer (EOC, ~90%), germ cell tumors (~3%), and stromal cell tumors 
(~6%) (Chen et al 2003) (Figure 1).  
EOC is a heterogeneous disease that has several histological subtypes 
with different origins and molecular profiles (Vaughan et al 2011). The most 
common histological subtype is papillary serous carcinoma that represents 50-
60% of all cancers. Other subtypes include endometrioid (25%), clear cell (4%), 
and mucinous (4%) carcinoma (Farley et al 2008). High-grade serous ovarian 
cancers (HGS-OC) are derived from the surface of the ovary and/or the distal 
fallopian tube (Bowtell 2010). Endometrioid and clear cell ovarian cancers are 
derived from endometriosis, which is associated with retrograde menstruation 
from the endometrium (Wiegand et al 2010). Most invasive mucinous ovarian 
cancers are metastases to the ovary, often from the gastrointestinal tract, 
including the colon, appendix or stomach (Kelemen and Kobel 2011). These 
different histological subtypes have distinct molecular signaling pathways. 
Mutations in tumor protein p53 encoding gene TP53 occur in at least 96% serous 
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ovarian tumors and the breast cancer susceptibility protein type 1 and type 2 
(BRCA1 and BRCA2) are mutated in 22% of HGS-OC samples. Clear cell 
ovarian cancers have few TP53 mutations, but are characterized by recurrent AT 
rich interactive domain 1A (ARID1A) and phosphoinositide-3-kinase catalytic 
alpha polypeptide (PIK3CA) mutations. Endometrioid ovarian cancers are 
associated with frequent β1-catenin encoding gene CTNNB1, ARID1A and 
PIK3CA mutations, and harbor a lower rate of TP53 mutations, as compared to 
serous cancers. Mucinous ovarian tumors are characterized by prevalent v-Ki-
ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (2011). As 
epithelial OC is the major form of OC, OC is used later on. 
OC is the ninth most common cancer in women (not counting skin cancer) 
and the fifth cause of cancer death of women in United States. About 21,990 
women were diagnosed with and 15,460 women died of OC in 2011 
(www.cancer.gov). The lethality of OC is mainly due to the inability to detect the 
disease at an early stage, and the lack of effective therapies for advanced-stage 
disease. About 62% of ovarian cancer cases are diagnosed after the cancer has 
already metastasized (www.seer.cancer.gov), and advanced stage OC has only 
a 27% 5 year survival rate. Therefore, studies on understanding the mechanisms 
of OC metastasis may lead to potential targets that could be investigated for the 
development of more efficient treatment modalities for this disease. 
 Metastasis is a multistep process; the key steps being detachment of 
malignant cells from the primary tumor, migration to and proliferation at distant 
organs. OC differs from other hematogenously metastasizing tumors by 
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disseminating within the peritoneal cavity (Figure 2). To detach from the primary 
tumor, cancer cells undergo epithelial-mesenchymal transition (EMT) to lose their 
epithelial characteristics, including their apical-basal polarity and specialized cell-
cell contacts, and acquire a migratory mesenchymal cell phenotype, which allows 
them to move away from their site of origin and spread to distant organs or 
tissues (Kalluri and Weinberg 2009). After dissociation from the original site, OC 
cells aggregate as multicellular spheroids and float in the peritoneal fluid (Allen et 
al 1987). The OC spheroids must overcome anoikis and hypoxic conditions in the 
peritoneal milieu, and attach to the mesothelium which covers all organs within 
the peritoneal cavity through several mechanisms, such as CD44 interaction with 
hyaluronic acid (Strobel et al 1997) (Lessan et al 1999), CA125/MUC16 
interaction with mesothelin on mesothelial cells (Rump et al 2004), and β1 
integrin interaction with fibronectin, laminin and collagen in the extracellular 
matrix (ECM) (Burleson et al 2004). After attachment, OC cells invade into the 
submesothelial basement membrane via proteolysis by matrix 
metalloproteinases (MMPs) and proliferate on abdominal organs such as the 
peritoneum, omentum, liver, stomach, colon, and diaphragm (Naora and Montell 
2005).  
Ascites is commonly found in ovarian cancer patients at advanced stage. 
Secretion of vascular endothelial growth factor (VEGF) by OC cells may increase 
vascular permeability and promote the ascites formation (Byrne et al 2003). 
Malignant ascites contains many growth factors, such as transforming growth 
factor-beta (TGF-β) (Abendstein et al 2000), platelet derived growth factor 
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(PDGF) (Matei et al 2006), vascular endothelial growth factor (VEGF) (Yabushita 
et al 2003), lysophosphatidic acid (LPA) (Xu et al 1995), cytokines, such as IL-6 
(Offner et al 1995), and other extracellular matrix constituents. These factors can 
promote cancer cells’ proliferation (Mills et al 1990), survival (Lane et al 2007), 
adhesion and invasion (Ahmed et al 2005). A proteomic analysis of 4 ascites 
samples from serous OC patients identified 80 overexpressed proteins that are 
involved in cell proliferation, differentiation, adhesion, migration, angiogenesis, 
proteolysis, and anti-apoptosis (Gortzak-Uzan et al 2008). Thus the ascites 
renders a favorable microenviroment to facilitate tumor growth and metastasis. 
 
Figure 1: Three cell types in the ovary. There are three types of cells in ovary: 
surface epithelial cells that cover the ovary, germ cells that develop into eggs, 
and stromal cells that support the organ’s structure and produce steroid 
hormones. 
 
  Germ cell 
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Figure 2: OC metastasis is a multistep process. 1. OC cells exfoliate from the 
primary site into the peritoneal cavity. Single cells undergo anoikis, while 
spheroids survive in the peritoneal cavity. 2. Spheroids adhere to the mesothelial 
lining in peritoneal cavity. 3. Spheroids dissociate and OC cells migrate on the 
mesothelial lining. 4. OC cells invade into the sub-mesothelial basement 
membrane. 5. OC cells proliferate at distant sites in the peritoneal cavity 
generating metastatic implants. 
 
 
 
 
 6 
1.2 Tissue Tansglutaminase (TG2) 
1.2.1 Transglutaminase family 
Transglutaminase (TGase, EC 2.3.2.13) is a protein family consisting of 9 
family members: a structural protein, band 4.2, which lacks catalytic activity and 
is expressed specifically in erythrocytes; and 8 enzymes, the factor XIII α subunit 
(FXIIIA) and TG 1-7.  
So far, only 7 members of the family have been isolated and characterized 
at protein level (Table 1). They are: 1) FXIIIA, is essential for blood coagulation 
(Lorand 2001); 2) TG1, also called keratinocyte TGase, involves in keratinocyte 
differentiation (Rice et al 1992); 3) TG2, the tissue transglutaminase, is a 
multifunctional protein, details will be discussed later; 4) TG3, the epidermal/hair 
follicle TGase, that together with TG1 is involved in the assembly of the 
epidermal cornified cell envelope (CE), a structure formed beneath the plasma 
membrane in terminally differentiating stratified squamous epithelia, and is 
essential for skin maturation and integrity (Kalinin et al 2001); 5) TG4, the 
prostate specific TGase, involved in semen coagulation, is essential for sperm 
maturation (Porta et al 1986); 6) TG5, also called TGx, contributes to 
keratinocyte differentiation and CE assembly (Candi et al 2002); and 7) band 4.2, 
also called ATP-binding erythrocyte membrane protein band 4.2, is important in 
the regulation of erythrocyte shape and mechanical properties (Korsgren et al 
1990). 
The other 2 lesser studied TG family members, TG6 and TG7, also called 
TGy and TGz, were identified at DNA level (Grenard et al 2001). All TGase 
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encoding genes are closely related and have similar sequence and gene 
structure. The genes for FXIIIA (F13A1) and TG1 (TGM1) consist of 15 exons 
and 14 introns, whereas TGM2-7 (genes for TG2-7) and EPB42 (band 4.2 
encoding gene) consist of 13 exons and 12 introns. These genes are scattered 
on different chromosomes: chromosome 3 for TGM4, 6 for F13A1, 14 for TGM1, 
15 for TGM5, TGM7, and EPB42, and 20 for TGM2, TGM3, and TGM6. Given 
the high degree of similarity in gene structure, protein primary and three-
dimensional structure, and their catalytic function, TGs genes are considered to 
have evolved from a common ancestral gene despite their distinct distribution in 
the human genome (Grenard et al 2001).  
All TGase family members share 4 distinct domains: an N-terminal β-
sandwich, a α/β catalytic core, and 2 C-terminal β-barrel domains (Yee et al 
1994) (Liu et al 2002) (Figure 3). Similar to papain (EC 3.4.22.2) and the papain-
like cysteine proteases, the catalytic core of TGase contains a Cys277-His335-
Asp358 triad. Band 4.2 is catalytically inactive because it lacks this cysteine 
residue. TGase catalyzes three types of Ca2+-dependent reactions: 
transamidation, esterification, and hydrolysis (Iismaa et al 2009). All three 
reactions involve 2 steps: acylation and deacylation. During the first step, a 
glutamine-containing protein or peptide acts as the acyl donor or amine acceptor 
substrate, which reacts with the Cys277 of the enzyme (acyl acceptor) to form a 
γ-glutamyl thioester intermediate, with ammonia released as a by-product. The 
acylation is followed either by a direct attack by water (hydrolysis/deamidation) or 
by binding of a second amine donor (transamidation) or an alcohol 
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(esterification). Transamidation results in either protein cross-linking, where a 
glutamine residue is cross linked to a lysine residue via a ε- (γ-glutamyl)-lysine 
isopeptide bond; or amine incorporation, where a primary amine is incorporated 
into a glutamine residue of the acceptor protein (Figure 4). The first TGase 
(which is designated TG2) was identified on the basis of its ability to incorporate 
amines into proteins (Sarkar et al 1957). Ca2+-dependent amine incorporation 
remains the main method to detect TG activity. 
Protein Tissue 
distribution 
Cellular 
localization 
Gene Gene map 
locus 
Function 
FXIIIA platelets Cytosol, 
extracellular 
F13A1 6p24-25 blood coagulation 
TG1 keratinocytes Cytosol, 
membrane 
TGM1 14q11.2 Keratinocyte 
differentiation 
TG2 ubiquitous Cytosol, 
nucleus, 
membrane, 
extracellular 
TGM2 20q11-12 multiple 
TG3 Squamous 
epithelium 
cytosol TGM3 20q11-12 Cell envelope (CE) 
formation 
TG4 prostate unknown TGM4 3q21-22 Semen coagulation 
TG5 ubiquitous unknown TGM5 15q15.2 CE formation, 
keratinocyte 
differentiation 
TG6 unknown unknown TGM6 20q11 unknown 
TG7 ubiquitous unknown TGM7 15q15.2 unknown 
Band 
4.2 
cells of the 
erythroid lineage 
membrane EBP42 15q15.2 erythrocyte 
membrane 
integration 
 
Table 1: Tansglutaminase family members. There are 9 members in the 
family: 8 enzymes including factor XIII α subunit (FXIIIA) and TG1-7, and non-
enzymatic protein band 4.2. Each member has different tissue distribution, 
cellular localization and functions as shown in the table. 
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Figure 3: Schematics of TGase domains. TGases share 4 distinct domains: an 
N-terminal β-sandwich, a α/β catalytic core (containing the Cys277-His335-Asp358 
catalytic triad), and 2 C-terminal β-barrel domains. 
 
 
 
 
Figure 4: Catalytic activity of TGases. TGases catalyze 3 types of Ca2+-
dependent reactions: transamidation, hydrolysis, and esterification. In all these 
reactions, a glutamine-containing protein or peptide acts as the major substrate. 
It reacts with a lysine-containing protein or peptide to cause crosslinking of the 2 
substrates. TG2 reacts with a polyamine to cause amine incorporation into the 
glutamine-containing protein or peptide. TG2 reacts with H2O to cause 
deamidation. It reacts with an alcohol to cause esterification.  
Gln - C      + NH2R            Glu - C       + NH3  
O O 
NH2 NHR 
Transamidation/ 
amine incorporation 
Gln - C       + NH2-Lys               Glu - C            + NH3  
O O 
NH2 NH-Lys 
Transamidation/ 
crosslinking 
Gln - C       + H2O            Glu - C       + NH3  
O O 
NH2 OH 
Deamidation/hydrolysis 
Gln - C      + ROH            Glu - C        + NH3  
O O 
NH2 OR 
Esterification 
Ca2+ 
Ca2+ 
Ca2+ 
Ca2+ 
COOH   NH2 
catalytic triad 
C277 H335 D358 
      β-sandwich             α/β catalytic core                β-barrel 1          β-barrel 2 
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1.2.2 Tissue transglutaminase is a multifunctional protein 
Tissue transglutaminase (TG2) is distinguished from other TGases by 
several unique characteristics: ubiquitous expression, widespread localization, 
ability to bind to and hydrolyze guanine nucleotides, and its non-enzymatic 
function involved in cell-matrix interaction (Figure 5). The ubiquitous distribution 
of TG2 is mainly due to its high expression on vascular endothelium and smooth 
muscle cells (Thomazy and Fesus 1989). TG2 is located mostly in the cytosol 
(~73%), and partly on the plasma membrane and in the ECM (~20%). A small 
proportion of TG2 (~7%) is localized in the nucleus (Bruce and Peters 1983). 
TG2 acts as a multifunctional protein due to its multiple functional domains and 
its functions vary depending on the protein’s cellular localization and its 
regulators. Ca2+ and GTP are two important regulators that inversely regulate the 
protein’s TGase and GTPase activity via an allosteric modulation of TG2 
conformation (Di Venere et al 2000). 
Folk et al demonstrated that Ca2+ induced a conformational change of 
purified guinea pig liver transglutaminase that promoted its enzymatic activity 
(Folk et al 1967). TG2 can bind 6 Ca2+; 5 of the 6 Ca2+-binding sites having been 
identified around the catalytic core (Kiraly et al 2009). However, the crystal 
structure of Ca2+-bound TG2 is still unresolved. Pinkas et al reported a TG2 
crystal structure with exposed active site using a pentapeptide Ac-P(DON)LPF-
NH2, which acts as an irreversible TG2 inhibitor (Pinkas et al 2007). Based on 
the crystal structure of Ca2+-bound FXIIIA (Fox et al 1999) and TG3 (Ahvazi et al 
2002), it has been suggested that Ca2+ binding opens a channel to expose the 
active site of TG2, which then can exert its enzymatic activity.
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Figure 5: TG2 localization and corresponding functions. 1) TG2 is located 
mostly in the cytosol (70-80%), where the protein acts as GTPase (Gh). Gh 
stimulates phospholipase C (PLC)-mediated inositol phosphate (IP) production 
after coupling with α1-adrenergic receptors, TXA2 TPα, and oxytocin receptor. 2) 
Approximately 7% of TG2 is located in the nucleus. Nuclear TG2 acts as a cross-
linking enzyme, a G-protein (Singh et al 1995), and a protein kinase. As a protein 
kinase, TG2 phosphorylates p53, Rb, and the histones H1, H2A, H2B, H3, and 
H4. 3) Cell surface TG2 can form ternary complexes with integrins and 
fibronectin (FN) to facilitate cell adhesion and migration. 4) Extracellular TG2 has 
transamidating activity due to high extracellular Ca2+ concentrations.  Many of the 
ECM components are substrates for TG2. Extracellular TG2 also interacts with 
syndecan 4 to form a FN-TG2-sydecan4 complex with or without integrins, and 
this complex is involved in the formation of focal adhesions and in the syndecan 
mediated signaling pathway. 
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Achyuthan et al found that guanosine 5’-triphosphate (GTP) could bind to 
guinea pig liver transglutaminase and inhibit its transamidation activity, a process 
which can be reversed by calcium. Guanosine diphosphate (GDP) binding also 
inhibited transglutaminase activity, but to a lesser extent than GTP. Guanosine 
monophosphate (GMP) didn’t inhibit the enzyme activity (Achyuthan and 
Greenberg 1987). Later, purified guinea pig liver transglutaminase was reported 
to exert a GTPase activity to hydrolyze GTP with a Km of 4.4 μM (Lee et al 1989). 
By purifying the α1-adrenergic agonist-receptor-G-protein ternary complex, Im et 
al found a 74-kD GTP binding protein (G-protein), named Gαh (Im and Graham 
1990), which forms a heterodimer with a 50-kD subunit Gβh (Im et al 1990), the 
inhibitory regulator of Gαh (Baek et al 1996a). By sequencing the newly found G-
protein, Gαh was identified as TG2, exerting both transglutaminase activity and 
G-protein coupled receptor (GPCR) signal transduction function (Nakaoka et al 
1994). Unlike the heterotrimeric G proteins and the Ras superfamily small 
GTPases, TG2 doesn’t have a common GTP-binding motif NKXD, but contains a 
unique nucleotide binding pocket for the nucleotide (Iismaa et al 2000). The 
crystal structure of TG2 in complex with GDP revealed a unique GDP-binding 
site located between the catalytic core and β-barrel 1 domain. Several amino 
acids including Lys173 and Phe174 from the catalytic core, Arg478, Val479, 
Met483, Arg580, Leu582, and Tyr583 from the β-barrel 1 form a hydrophobic 
pocket to bind GDP. Arg580 seems to be indispensable for GDP binding, which 
forms two ion pairs with the α- and β-phosphates of the nucleotide (Liu et al 
2002). Mutation of Arg580 abolished GTP-binding but didn’t affect TGase activity 
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(Begg et al 2006b). This GDP-bound TG2 exhibits a closed conformation, where 
Cys277, the essential residue for TGase activity is blocked by 2 loops within the 
β-barrel 1 domain. Furthermore, Tyr516 forms a hydrogen bond with Cys277, 
which makes Cys277 inaccessible to the substrate. Thus, GTP/GDP binding 
induces a compact, catalytically inactive conformation of TG2. GTP binding to 
Arg580 is critical for TG2 to adopt the compact form while mutation of Arg580 
destabilizes the compact form, indicating that Arg580 is an important allosteric 
site for TG2 conformational/functional regulation (Begg et al 2006b).  
Although TG2 has a different nucleotide binding mechanism from 
heterotrimeric GTPases, the signaling transduction cascade is similar. Upon 
binding of the agonist, the GPCR undergoes a conformational change which 
activates the Gαh by releasing GDP and binding to GTP. Once bound to GTP, 
Gαh dissociates from both the receptor and Gβh. GTP-bound Gαh then interacts 
with the effector which produces a second messenger to amplify the signal. Once 
GTP is cleaved to GDP and Pi by the GTPase function of Gαh, GDP-bound Gαh 
dissociates with the effector and reassociates with Gβh, and thus completing an 
activation/deactivation cycle of GTPase (Im et al 1990). Ligand: Gαh was first 
found in a ternary form with an adrenergic agonist and a α1-adrenoceptor (AR) 
(Im and Graham 1990). Catecholamines such as epinephrine and norepinephrine 
can bind to and activate α1-adrenoceptor. Receptor: α1-AR is a transmembrane 
glycoprotein and belongs to the GPCR superfamily with seven α-helical 
transmembrane-spanning domains connected by hydrophilic loops exposed to 
the intra- and extracellular environment. The intracellular loops bind and activate 
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the receptor-coupled G-proteins. They are classified into 3 subtypes: α1A, α1B, 
and α1D based on molecular structure, function, and signaling (Graham et al 
1996). α1-AR activates phosphoinositide-specific phospholipase C (PI-PLC) via α 
subunit of Gq family (Wu et al 1992). TG2/Gh interacts with the third intracellular 
loop of α1B- and α1D- but not α1A-AR, and this interaction is not affected by 
transamidation inactive TG2 mutant C277S (Chen et al 1996). Multiple regions at 
the C-terminal β-barrel domains of TG2 including L547−I561, R564−D581, and 
Q633−E646 interact with α1B-AR to mediate the signal to downstream effectors 
(Feng et al 1999). TG2/Gh also interacts with thromboxane A2 (TXA2) receptor 
TPα but not with TPβ to activate PLC (Vezza et al 1999), while thromboxane A2 
(TXA2) is a prostaglandin derivative produced during arachidonic acid 
metabolism (Nakahata 2008). Except for α1-AR and TPα, TG2/Gh also couples 
with oxytocin receptor to activate PLC, while oxytocin is a neurohypophysial 
nonapeptide hormone (Baek et al 1996b). Effector: Phospholipase C (PLC) 
δ 1 was reported to be the effector of Gh (Feng et al 1996), which has an 8-amino 
acids recognition site located at the C-terminal β-barrel 2 domain (Leu665-
Lys672) involved in interaction with PLC (Hwang et al 1995). PLC (EC 3.1.4.11) 
is a family of proteins including PLCβ, γ, δ, ε, ζ and η, which share a structure 
with an N-terminal pleckstrin homology (PH) domain, 4 EF hands, a catalytic TIM 
barrel, and a C-terminal C2 domain (Bunney and Katan 2011). The residues 
T721-L736 located in the C2 domain of PLCδ 1 are involved in the interaction 
with TG2 (Kang et al 2002). PLC hydrolyses phosphatidylinositol 4,5-
bisphosphate (PIP2) to two second messengers: 1,2-diacylglycerol (DAG), an 
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activator of protein kinase C (PKC) (EC 2.7.11.13), and inositol 1,4,5-
trisphosphate (IP3), which binds to the IP3-sensitive Ca2+ channel at 
endoplasmic reticulum (ER) and triggers Ca2+ releasing to cytoplasm (Exton 
1996). Effects: α1-ARs are important mediators of sympathetic nervous system 
responses, particularly arteriolar smooth muscle contraction and cardiac 
contraction, which are critical for cardiac function and blood pressure 
homeostasis (Graham 1990). TXA2 TPα is distributed on a variety of cells, 
including platelets, vascular smooth muscle cells, and macrophages. Upon 
activation, it exerts potent biological activities including platelet aggregation and 
secretion, vasoconstriction, and mitogenesis (Nakahata 2008). Oxytocin receptor 
is widely distributed in the central nervous system: the olfactory system, the 
basal ganglia, the limbic system, the thalamus, the hypothalamus, some cortical 
regions, the brainstem, and the spinal cord, where it involves in maternal, sexual, 
social, and stress-related behavior (Tribollet et al 1992). 
Except for GTP, TG2 also binds and hydrolyzes adenosine triphosphate 
(ATP). ATP binding inhibits GTP hydrolysis but does not inhibit TGase activity 
(Lai et al 1998). ATP binds to the same pocket as GDP, but forms different 
hydrogen bonds and ions interaction with TG2. The four residues Arg476, 
Arg478, Val479 and Tyr583 are involved both in GDP and ATP binding to TG2. 
The residue Arg580, which is important for GTP/GDP binding, is not involved in 
ATP binding (Han et al 2010). By purifying the insulin-like growth factor-binding 
protein-3 (IGFBP-3) kinase in T47D breast cancer cells, Mishra et al found that 
TG2 on the cell membrane can act as kinase to phosphorylate IGFBP-3 and 
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IGFBP-5 at multiple serine residues in the central domain. This kinase activity is 
inhibited by calcium (Mishra and Murphy 2004). The authors later identified more 
substrates for TG2 as a kinase. They include P53 (Mishra and Murphy 2006), 
H1, H2A, H2B, H3, and H4 histones (Mishra et al 2006), and retinoblastoma 
protein (Rb) (Mishra et al 2007). Phosphorylation of P53 by TG2 alters the 
interaction between p53 and Mdm2, and phosphorylation of Rb by TG2 
destabilizes the Rb/E2F1 complex. These results indicate that TG2 may act as a 
kinase to promote the function of some tumor suppressor proteins. However, all 
these studies were performed in vitro, and additional cell-based or in vivo 
analyses need to validate the kinase function of the protein. 
Besides the functions mentioned above, Hasegawa et al reported a novel 
function of TG2 as a protein disulfide isomerase (PDI) by showing that TG2 
converts the reduced/denatured inactive RNase A molecule to the native active 
enzyme, and this function is inhibited by bacitracin, a PDI inhibitor, but is not 
inhibited by calcium or GTP (Hasegawa et al 2003).  
As a multifunctional protein, TG2 exerts different roles in different cellular 
compartments. Since Smethurst et al reported that at least 10μM Ca2+ is required 
to detect the transamidating activity of TG2 in a permeabilized cell system 
(Smethurst and Griffin 1996) and the intracellular Ca2+ concentration is relatively 
low (~100nM Ca2+), it is believed that cytosolic TG2 acts as a GTPase, and not 
as a transamidating enzyme. However, the exact concentration of Ca2+ 
necessary for the enzyme’s activation under physiological conditions is not clear. 
Basel level of transamidating TG2 activity was detected in Chinese-hamster 
 17 
ovary cells (Fesus and Tarcsa 1989). Kiraly et al also described that enzymatic 
TG2 activity has been reported in many resting cells (Kiraly et al 2011), 
suggesting that under certain conditions intracellular TG2 can act as a TGase. 
In contrast with cytosolic TG2, the extracellular matrix (ECM) TG2 exerts 
transamidating activity due to high extracellular Ca2+ concentrations (~1.2mM 
Ca2+) (Turner and Lorand 1989). Since components of the ECM are TG2 
enzymatic substrates: FN, collagens, vitronectin, fibrinogen, osteopontin, laminin, 
etc., extracellular TG2 is involved in the assembly, remodeling, and stabilization 
of ECM in various tissues (Aeschlimann and Thomazy 2000). Extracellular TG2 
also interacts with syndecan 4 to form a FN-TG2-syndecan 4 complex with or 
without integrin. This complex is involved in the formation of focal adhesions and 
in syndecan mediated signaling (Wang et al 2010).  
Cell surface TG2 forms ternary complexes with integrins and fibronectin 
(FN) in which the three proteins interact with each other, facilitating cell adhesion 
and migration (Turner and Lorand 1989). Interaction with integrins makes it 
possible for TG2 to be involved in integrin-dependent signal transduction, 
including in the focal adhesion kinase (FAK) and GTP-binding proteins Raf-1 and 
Rho regulated signaling pathways (Hang et al 2005). These interactions do not 
require Ca2+ and are independent of the transamidating and GTPase activity of 
the enzyme. Since most integrin ligands in the ECM are TG2 enzymatic 
substrates: FN, collagens, vitronectin, fibrinogen, osteopontin, laminin, etc., 
extracellular TG2 is involved in the assembly, remodeling and stabilization of 
ECM in various tissues (Aeschlimann and Thomazy 2000).  
 18 
About 7% TG2 exists in the nucleus. The mechanism of nuclear 
translocation of TG2 is still under study. Importin-α3, a nuclear transporter 
protein, has been reported to be implicated in the active transport of TG2 into the 
nucleus (Peng et al 1999). TG2 has a putative nuclear localization signal (NLS) 
motif KQKRK between residues 598-602, which shares high homology with the 
NLS in the influenza virus NS1 non-structural protein (Greenspan et al 1988). 
TG2 also has a putative leucine-rich nuclear export signal (NES) motif 
LHMGLHKL at residues 657-664, which can be recognized by the nuclear 
exporter exportin1/Crm1p (Stade et al 1997). Therefore, the balance between the 
import and the export of TG2 regulates the amount of nuclear accumulation of 
TG2. TG2 acts as cross-linking enzyme (Lesort et al 1998), a G-protein (Singh et 
al 1995), and a protein kinase in the nucleus. 
Therefore, TG2 acts as a multifunctional protein in different cellular 
compartments. Interestingly, TG2 knockout mice are viable and develop normally 
(De Laurenzi and Melino 2001) (Nanda et al 2001). To explain this normal 
phenotype, it has been speculated that the functions of TG2 may be 
compensated by the other members of the transglutaminase family. Further 
study of the TG2 null animals revealed impaired wound healing, defective 
phagocytosis, and maturity onset diabetes of young (MODY) (Bernassola et al 
2002) (Szondy et al 2003). More detailed study of TG2 knockout mice is needed 
to fully understand the functions of this protein in vivo. 
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1.2.3 TG2 Involvement in Disease: 
Given the complexity of its enzymatic and non-enzymatic functions, TG2 is 
involved in a number of inflammatory disorders, in wound healing, fibrosis, 
autoimmune diseases, neurodegenerative diseases, and cancer.  
 Our laboratory previously identified TG2 as an upregulated gene in OC 
cells compared with normal ovarian epithelial cells (Matei et al 2002). 
Overexpression of TG2 protein levels was also demonstrated in ovarian cancer 
cells, tumors and ascitic fluid (Satpathy et al 2007). Our group demonstrated that 
overexpressed TG2 facilitates OC intraperitoneal (i.p.) dissemination by 
enhancing cancer cell adhesion to the ECM and interaction with  β1 integrin. 
Stable knockdown of TG2 in the OC cell line SKOV3 markedly affected cell 
adhesion, migration in vitro and i.p. dissemination in nude mice (Satpathy et al 
2007). Recently, our laboratory reported that TG2 can upregulate matrix 
metalloproteinase-2 (MMP-2), which is an important mediator of ECM 
degradation and facilitates tumor cell invasion (Satpathy et al 2009). TG2 
overexpression was also reported in other cancers such as breast cancer 
(Herman et al 2006), pancreatic cancer (Verma et al 2006), melanoma (Fok et al 
2006), glioblastoma (Yuan et al 2007), and meningioma (Yuan et al 2008). The 
reported functions of TG2 in cancer were focused on metastasis and 
chemoresistance. However, the mechanisms by which TG2 is associated with 
cancer metastasis and chemoresistance are not fully understood. The function of 
TG2 in cancer is still an enigma since TG2 displays both pro- and anti-apoptotic 
effects in cells (Fesus and Szondy 2005). 
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TG2 has been linked to apoptosis, acting either as a promoter or as an 
antagonist, through mechanisms that are specific to the cellular context. Under 
physiological conditions, the intracellular enzymatic activity of TG2 is negatively 
regulated by low concentrations of Ca2+ and high level of guanosine 
triphosphate. However, in the late phases of apoptosis, when massive 
intracellular Ca2+ influx occurs, the enzymatic function of TG2 is activated leading 
to cross-linking of cytosolic proteins and finalization of the cell death process 
(Lorand and Graham 2003). In contrast, TG2 has an antiapoptotic role in 
malignant cells. For instance, in breast and pancreatic cancer cells, TG2 
activates nuclear factor kappa B (NF-κB) by cross-linking the inhibitory subunit 
inhibitor of kappa B α (IκBα). This leads to its polymerization and displacement 
out of the complex with NF-κB (Park et al 2006) (Mann et al 2006). This process 
depends on TG2′s enzymatic activity and leads to constitutive activation of NF -
κB. In leukemia HL60 cells, TG2-mediated transamidation protects the 
retinoblastoma gene product from caspase-induced degradation and promotes 
cell survival (Boehm et al 2002). In colon cancer cells HCT116, TG2 suppresses 
apoptosis by protecting the cleavage and activation of caspase-3, through protein 
cross-linking (Yamaguchi and Wang 2006). Furthermore, TG2 is involved in 
anchoring epithelial cells to the extracellular matrix; this process leads to 
activation of ‘outside-in’ signaling that ultimately promotes cell survival (Akimov et 
al 2000). The interaction between TG2, fibronectin and integrins not only 
promotes cancer cell adhesion and migration, but also promotes cancer cell 
proliferation and survival by upregulating cell survival and anti-apoptotic signaling 
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pathways, such as focal adhesion kinase (FAK) and PI3K/Akt pathway (Verma et 
al 2008). These observations have direct applications for understanding the 
process of chemotherapy resistance and have incited an interest in developing 
TG2 inhibitors as anticancer therapy (Yuan et al 2005).  
 
1.3 Transforming growth factor-beta (TGF-β)  
Transforming growth factor-beta is a multifunctional polypeptide that 
signals through its serine-threonine kinase receptors and intracellular Smad 
effectors to regulate development, differentiation, and homeostasis. 
Ligand: Transforming growth factors (TGFs) were first discovered as 
secreted polypeptides ranging from 7 to 25kDa in sarcoma virus-transformed 
fibroblasts, which can induce anchorage-independent growth of the fibroblasts in 
soft agar (de Larco and Todaro 1978). Further purification identified two distinct 
polypeptides, which were named TGF-α and TGF-β (Anzano et al 1983). TGF-α 
binds to the EGF receptor and competes with EGF to induce normal rat kidney 
cells’ colony formation in soft agar. There are 3 isoforms in mammalian TGF-β 
family: TGF-β1, TGF-β2, and TGF-β3. As TGF-β1 is the prototype, TGF-β2 was 
purified from porcine platelets (Cheifetz et al 1987), and TGF-β3 was identified at 
the cDNA level (ten Dijke, 1988). TGF-βs 1–3 belong to the transforming growth 
factor beta superfamily which contains more than 30  polypeptide growth factors 
including TGF-βs (1–3), activins (A, B), inhibins (A, B), bone morphogenetic 
proteins (BMPs 1–20), growth differentiation factors (GDFs) including myostatin, 
nodal, leftys (1,2), and anti-Mullerian hormone (AMH) or Müllerian-inhibiting 
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substance (MIS). All family members share a similar structure: the disulfide-
linked dimeric polypeptide.  
The TGF-β superfamily ligands are secreted as latent form (Lawrence et 
al 1984) comprising a large dimeric N-terminal prodomain (latency-associated 
propeptide, LAP) and a C-terminal mature TGF-β (Gentry et al 1988), called 
small latent complex (SLC). The mature ligands are cleaved from the prodomain 
by furin-like enzymes during secretion (Dubois et al 1995). After cleavage, the 
propeptide LAP remains associated with the TGF-β dimer via non-covalent 
electrostatic interaction and inhibits TGF-β’s binding to its receptors. Most cells 
secrete latent TGF-β as large latent complex (LLC), where the LAP associates 
with the latent TGF-β binding protein (LTBP) via a disulfide bond (Saharinen et al 
1996). LTBPs are required for correct assembly and secretion of TGF-βs 
(Miyazono et al 1991). LTBPs belong to the LTBP/fibrillin family, including LTBP 
1-4 and fibirillin 1-2, which are the main components of extracellular microfibrils. 
(Taipale et al 1996) (Ramirez and Pereira 1999). LTBPs are 125-240 KD proteins 
characterized by 14-20 copies of epidermal growth factor (EGF)-like repeats and 
4 copies of eight cysteine (8-cys) repeats (Hyytiainen et al 2004). LTBPs bind to 
LAP via the third 8-cys repeat (Saharinen and Keski-Oja 2000), and localize the 
latent complex to the extracellular matrix (ECM) via the other three 8-cys repeats 
(Taipale et al 1994) (Unsold et al 2001). Thus the ECM bound latent complexes 
serve as a reservoir for TGF-β. Only after TGF-β is released from the latent 
complex, it binds to its cell surface receptors and initiates the intracellular 
signaling cascade. Release of active TGF-β requires two steps: first, to release 
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the TGF-β latent complex from ECM by cleavage of LTBP at its protease 
sensitive hinge region, which is between the N-terminal ECM binding domain and 
the C-terminal LAP binding domain. This can be achieved by many proteinases 
in the serine proteinase family, such as plasmin, chymase, and elastase (Taipale 
et al 1992) (Taipale et al 1995); second, to activate TGF-β by disruption of the 
non-covalent interaction between LAP and TGF-β. This can be achieved in vitro 
by physicochemical activation such as acid or base, heat and chaotropic agents 
treatment (Brown et al 1990). Under physiological situations, several 
mechanisms for TGF-β activation have been reported. A number of proteases 
including plasmin (Sato and Rifkin 1989) and MMP-2/9 (Yu and Stamenkovic 
2000) can degrade LAP and thus release the active TGF-β. Thrombospondin 
(TSP) can release the active TGF-β by inducing a conformational change of LAP 
(Murphy-Ullrich and Poczatek 2000). Integrin αvβ6 can bind to the Arg-Gly-Asp 
(RGD) sequence in LAP, induce a conformational change, and activate TGF-β 
(Munger et al 1999). Normally, these two steps are finely tuned because they are 
critical for the regulation of TGF-β activity. For example, plasmin and MMP-2/9 
not only can activate TGF-β, but also induce degradation of ECM, which is 
important in the process of TGF-β secretion and storage. Moreover, TGF-β 
induces the expression and activity of plasminogen activator inhibitor (PAI) 
(Laiho et al 1986) and tissue inhibitor of metalloproteinase-1 (TIMP-1) (Edwards 
et al 1987), thus a feed-back inhibitory loop is formed to modulate TGF-β activity. 
Deregulation of TGF-β activity will lead to pathological conditions such as fibrotic 
diseases, chronic inflammation and cancer. 
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Receptors: Active TGF-β signals through a heteromeric complex of type I 
and type II transmembrane serine-threonine kinase receptors. The ligand brings 
the receptors together in a heterotetrameric complex in which the type II 
receptors phosphorylate and activate the type I receptors. The receptor 
serine/threonine kinase family comprises 12 members: 7 type I receptors (Activin 
receptor-like kinases, ALKs1-7) and 5 type II receptors (TβR-II, ActR-II, ActR-IIB, 
BMPR-II, and AMHR-II). Both types of receptors consist of an N-terminal 
extracellular ligand binding domain, a transmembrane region, and a C-terminal 
intracellular serine/threonine kinase domain, whereas the type I receptors contain 
a specific glycine-serine-rich sequence, called GS region. This sequence is 
located upstream of the kinase domain in type I receptors and, once 
phosphorylated by the type II receptors, confers a conformational change that 
switches this region from a binding site for inhibitor the 12-kDa FK506-binding 
protein (FKBP12) to a binding site for its substrates, the Smad family of 
transcription factors. This switch results in full activation of the type I receptor 
kinases (Huse M, Massague J. 2001). For some ligand-receptor interactions, co-
receptors, such as betaglycan, endoglin (Fonsatti et al 2001), and members of 
the EGF-Cripto, Frl-1, and Cryptic (EGF-CFC) family, are also required (Feng 
and Derynck 2005).  
Intracellular signal mediators: Smad is a term derived from Sma in 
Caenorhabditis elegans and Mad (Mothers against decapentaplegic) in 
Drosophila (Derynck et al 1996). There are 8 Smad proteins encoded in 
mammalian genome, and they are divided into 3 subgroups based on structural 
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and functional criteria. Smad1, Smad2, Smad3, Smad5, and Smad8 act as 
substrates for TGF-β family of receptors, referred as receptor-regulated Smads, 
or R-Smads. Smad 1, 5, and 8 are substrates for BMP and AMH receptors, 
Smad 2 and 3 are substrates for TGF-β, activin, and Nodal receptors. Smad 4, 
also called Co-Smad, is a common partner for R-Smads. Smad 6 and 7 are 
inhibitory Smads (I-Smads) that interfere with Smad-receptor and Smad-Smad 
interactions. Smads are modular proteins with an N-terminal Mad-homology 1 
(MH1) (conserved in all R-Smads and Smad4, lacked in I-Smads), a linker region 
and a C-terminal MH2 domain (conserved in all Smads). The MH1 domain 
participates in nuclear localization, DNA-binding, and protein–protein 
interactions. The MH1 domain binds to the sequence 5’-GTCT-3’, or its 
complement 5’-AGAC-3’, called the Smad-binding element (SBE), on target gene 
promoter region (Shi et al 1998). The linker domain recruits Smurf (Smad 
ubiquitination-related factor) ubiquitin ligases that regulate Smad and TGF-β 
receptor half-life. The MH2 domain is a major protein–protein interaction domain. 
It has a C-terminal conserved Ser-X-Ser motif, which can be phosphorylated by 
activated receptor serine-threonine kinase (Massague et al 2005). 
 TGF-β induced activation of the receptor complex leads to activation of 
Smad2 and Smad3 through direct phosphorylation by TGF-β RI. Phosphorylated 
Smad2 and Smad3 then form a trimeric protein complex with Smad4. Monomeric 
Smad proteins constantly shuttle in and out of the nucleus conferred by a lysine-
rich nuclear localization signal (NLS) in MH1 domain (Xiao et al 2001), but only 
the receptor-activated R-Smad/Co-Smad complexes favors their nuclear 
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accumulation (Schmierer and Hill 2005). In the nucleus, the active R-Smad/Co-
Smad complexes bind directly to cognate DNA sequence and associate with 
other transcription factors such as activating transcription factor 2 (ATF2) and 
cyclic AMP-responsive element-binding protein (CREB), co-activators CREB- 
binding protein (CBP) and p300 or co-repressors to activate or repress target 
gene transcription (Moustakas and Heldin 2009). Smad4 serves as co-activator 
for R-Smads by stabilizing the interaction between R-Smad, DNA and CBP/p300 
(Derynck and Zhang 2003). 
 Besides Smad-mediated transcription, TGF-β can activate other pathways 
such as mitogen-activated protein kinases (MAPKs) including extracellular 
signal-regulated kinase (Erk), p38 and c-Jun N-terminal kinase (JNK), 
phosphoinositide 3′ kinase  (PI3K), small GTPases of the Ras superfamily and 
NF-κB pathways  . TGF-β activates TGF-β-activated kinase 1 (TAK1), which can 
activate p38 MAPK through MKK3, activate JNK through MKK4, and activate NF-
κB through the Inhibitor of kappa B (IκB) kinase (Wang and Fu 2001) (Figure 6). 
 TGF-β in cancer: TGF-β exerts dual roles in cancer, as tumor suppressor 
at the early stages of tumorigenesis, through inhibition of epithelial cell 
proliferation, and as tumor promoter, at advanced stages, by enabling cancer 
cells to acquire the six hallmarks of cancer: cell proliferation, survival, immortality, 
angiogenesis, dissemination, and evading immunosurveillance (Tian et al 2011).   
 As a tumor suppressor, TGF-β inhibits cell proliferation by arresting cell 
cycle at the G1 phase via transcriptional regulation of target genes. TGF-β 
downregulates the expression of the growth-promoting transcription factors, c-
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Myc (Chen et al 2002) and Id1 (Kang et al 2003),  and upregulates the cyclin-
dependent protein kinase (CDK) inhibitors, p15INK4b, p21CIP and p27kIP1 (Siegel 
and Massague 2003).  While p15 inhibits the cyclin D/CDK4/6 complex, p21 
inhibits cyclin B/CDK1, and p27 preferentially target and antagonize cyclin 
E/CDK2 complex. Taking all the events together, TGF-β works in concert to 
inhibit the progression of cells through the cell cycle. 
 As a tumor promoter, TGF-β activates PDGF, MAPK, NF-κB and 
PI3K/AKT pathways to promote cancer cell proliferation and survival (Arsura et al 
2003) (Sanchez-Capelo 2005). TGF-β also acts as a potent inducer of 
angiogenesis, which is crucial for tumor growth, as blood vessels deliver 
nutrients and oxygen to the tumor cells. Studies using transgenic KO mouse 
models of components of the TGF-β signaling pathway such as TβRI, TβRII, 
ALK5, ALK1, endoglin, and Smad5 revealed that TGF-β signaling is essential for 
vascular development, including proliferation and differentiation of endothelial 
cells, maintenance of the integrity of the vessel wall, recruitment of smooth 
muscle cells, as well as the deposition of extracellular matrix (Goumans et al 
2009). TGF-β promotes tumor dissemination by inducing epithelial-mesenchymal 
transition (EMT), cell motility and invasion through both Smad-dependent and 
Smad-independent signaling pathways. TGF-β signals through Smad-mediated 
induction of Snail and Slug zinc-finger transcription factors to repress the E-
cadherin gene (Takano et al 2007). TGF-β is also reported to downregulate E-
cadherin expression via PI3K signaling pathway (Vogelmann et al 2005). TβRII-
mediated phosphorylation of polarity protein Par6 promotes the dissolution of 
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tight junctions and disassembly of the cytoskeleton (Ozdamar et al 2005). TGF-β 
acts as an immunosuppressor by inhibition of B or T lymphocyte proliferation, 
differentiation and survival. During tumor progression, TGF-β suppresses anti-
tumor immune response by regulating chemotaxis, activation, and survival of 
lymphocytes, natural killer cells, dendritic cells, macrophages, mast cells, and 
granulocytes to evade immune surveillance (Li et al 2006). Overall, as a tumor 
promoter, TGF-β functions to promote cancer cell proliferation and survival by 
activating cell survival signaling pathways, to promote tumor metastasis by 
inducing motility, invasion and angiogenesis, to help tumor cells evade 
immunosurveillance by repressing anti-tumor immune response. 
TGF-β in OC: In normal ovarian surface epithelial cells, TGF-β functions 
to inhibit epithelial proliferation (Berchuck et al 1992). However, this function is 
often lost in ovarian cancer, although the receptors and the downstream Smad 
signaling are intact including TGF beta 1, TGF beta RI, TGF beta RII, Smad2, -3, 
-4, and inhibitory Smad 6 and -7 (Yamada et al 1999) (Dunfield et al 2002). 
Moreover, the TGF-β ligand was found significantly increased in expression in 
both primary and recurrent OC compared with normal ovarian tissue (Henriksen 
et al 1995) (Bristow et al 1999). TGF-β1 and 2, but not 3, are secreted in ovarian 
cancer-associated ascites by both ovarian cancer cells and peritoneal 
mesothelial cells, and the secreted levels of TGF-β1 are higher than those of 
TGF-β2 (Abendstein et al 2000). It is possible that TGF-β plays a role in OC 
metastasis, as it significantly increases invasion of OC cells, but not of normal 
ovarian surface epithelial cells (NOSE) cells by increasing MMP-2 expression 
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and activity (Rodriguez et al 2001). In addition TGF-β1 induces EMT and MMP 
secretion in OC cells in a Smad-dependent signaling pathway (Do et al 2008). 
 
Figure 6: TGF-β signaling through Smad-dependent and Smad-independent 
pathways. TGF-β signals through a heteromeric complex of type I and type II 
transmembrane serine-threonine kinase receptors. In Smad-dependent pathway, 
TGF-β induced activation of the receptor complex leads to activation of Smad2 
and Smad3 through direct C-terminal phosphorylation by TGFβ RI. 
Phosphorylated Smad2 and Smad3 then form trimers with Smad4, and 
translocate into the nucleus, where they associate and cooperate with other DNA 
binding transcription factors to activate or repress target gene transcription. In 
Smad-independent pathway, TGF-β activates TGF-β-activated kinase 1 (TAK1), 
which can activate p38 MAPK through MKK3, activate JNK through MKK4, and 
activate NF-κB through inhibition of IkB. TGF-β also can activate small GTPases, 
PI3K/Akt, and Par6 to regulate cell plasticity, motility and survival. 
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1.4 Epithelial-Mesenchymal Transition (EMT) 
EMT is a biologic process by which adherent epithelial cells undergo 
morphological and molecular changes to gain a migratory mesenchymal cell 
phenotype. It is a critical step for many physiological and pathological conditions 
such as embryonic development, wound healing, fibrosis, tissue remodeling, and 
tumor progression. The reverse program, termed the mesenchymal-epithelial 
transition (MET), also occurs both during embryonic development and during 
several pathological processes (Boyer and Thiery 1993).  
EMT is characterized by the breakdown of cell junctions and loss of cell 
polarity, rendering epithelial cells motile and invasive (Thiery 2002). In cancer, 
EMT causes cells to lose epithelial characteristics and acquire a mesenchymal 
phenotype, initiating invasion and metastasis. A variety of stimuli trigger EMT and 
many of these signals appear to converge on the same critical endpoint: the 
altered expression and/or function of cadherins.  
Type I cadherins maintain stable cell-cell contacts through adherens 
junctions and desmosomes (Nagar et al 1996, Shapiro et al 1995). The 
extracellular immunoglobulin-like domains of E-cadherin bond neighboring cells 
through junctional complexes (Nagafuchi et al 1987, Patel and Gumbiner 1995). 
To preserve cellular shape and polarity, the intracellular domains of cadherins 
connect to the actin cytoskeleton through α-catenin and β-catenin (Cavey et al 
2008). Downregulation of E-cadherin expression in cancer cells is a critical 
disruptor of epithelial homeostasis, leading to increased cell invasiveness and 
adoption of a mesenchymal behavior. A “cadherin switch” has been described, 
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whereby E-cadherin loss in cancer cells is accompanied by gain of N-cadherin 
(Kuphal and Bosserhoff 2006), which is a marker of mesenchymal differentiation 
(Kim et al 2000). The molecular mechanisms of this switch, leading to increased 
cell motility and invasion (Hazan et al 2000, Nieman et al 1999) are not known. 
Loss of E-cadherin expression during cancer progression is regulated 
through genetic or epigenetic mechanisms. E-cadherin promoter 
hypermethylation leads to decreased expression level in metastatic breast and 
prostate cancer cells (Graff et al 1995, Tamura et al 2000). Genetic mechanisms 
regulating E-cadherin expression involve transcriptional repression at Ets sites or 
at palindromic E-boxes in the E-cadherin promoter (Hajra et al 2002). A number 
of transcriptional repressors are emerging as critical modulators of EMT, 
including the zinc-finger domain containing factors Snail, Slug, Zeb 1, Zeb 2 and 
the basic helix-loop-helix (HLH) factors E47 and Twist (Julien et al 2007, Moreno-
Bueno et al 2006, Olmeda et al 2007, Peinado et al 2007).  Their function is 
partly regulated by oncogenic pathways activated in cancer, particularly by ras 
(Boyer et al 1997), Src (Rodier et al 1995), Akt (Grille et al 2003, Larue and 
Bellacosa 2005), GSK-3β(Zhou et al 2004), and NF-κB (Chua et al 2007). In 
addition, integrin signaling triggered by interaction of cancer cells with the 
extracellular milieu (ECM) leads to activation of the integrin-linked kinase (ILK) 
(Fuchs et al 2008, Li et al 2003) and modulation of the activity and balance 
between the small GTPases Rho and Rac (Zondag et al 2000). In turn, ILK, Rho 
and Rac regulate E-cadherin dependent cell adhesiveness and control the 
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assembly of the actin filaments required for cell shape and motility (Fuchs et al 
2008, Zondag et al 2000).  
 
1.5 Ovarian Cancer stem cells 
Cells that have undergone EMT were reported to exhibit cancer stem cells 
(CSCs) phenotype (Mani et al 2008). CSCs, also called tumor-initiating cells, are 
cancer cells that possess characteristics associated with normal stem cells. They 
can undergo self-renewal (during cell division, one or both daughter cells retain 
the same biologic properties as the parent cell) to maintain tumor growth, and 
they also can differentiate into a heterogeneous population of cells that compose 
the tumor. CSCs are proposed to persist in tumors as a distinct population and 
cause relapse and metastasis by giving rise to new tumors (Soltysova et al 
2005). CSCs are chemoresistant (Gangemi et al 2009). CSCs can be identified 
and isolated using markers specific for normal progenitor or stem cells of the 
same organ (Visvader and Lindeman 2008). Several markers have been 
identified for isolation of cancer stem cells, including CD44/CD24 (Al-Hajj et al 
2003), CD133 (Singh et al 2004) (O'Brien et al 2007), ATP-binding cassette B5 
(ABCB5) (Schatton et al 2008), ALDH 1 (Ginestier et al 2007) as well as Hoechst 
33342 exclusion (Szotek et al 2006) (Hadnagy et al 2006). 
OC is a highly metastatic disease, and the metastasis process 
recapitulates the heterogeneity and morphology of the primary tumor. Moreover, 
although most patients with ovarian cancer achieve complete remission after 
surgical debulking and platinum-based chemotherapy, 70% of advanced stage 
ovarian cancer relapses. Even in stage I or II patients, the relapse rate is 20%–
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25% (Ushijima 2010). Patients with recurrent tumors develop chemoresistance 
and ultimately succumb to the disease. This evidence strongly suggests the 
existence of ovarian cancer stem cells, which are responsible for metastasis, 
recurrence, and chemoresistance. 
Ovarian cancer stem cells, also called ovarian cancer initiating cells 
(OCICs), were first identifided by Zhang et al (Zhang et al 2008). These 
CD44+CD117+ cells display several cancer stem cell characteristics: self-
renewal as assayed by spheroid formation in vitro, ability of differentiation, 
tumorigenicity in serial transplantation in NOD/SCID mice, and chemoresistance. 
These cells express stem cell markers (Bmi-1, stem cell factor, Notch-1, Nanog, 
nestin, ABCG2, and Oct-4). As few as 100 of the CD44+CD117+ cells are 
sufficient to generate tumors in NOD/SCID mice.  
CD44 is a 80-250KD transmembrane glycoprotein family involved in cell 
proliferation, cell differentiation, cell migration, angiogenesis, presentation of 
cytokines, chemokines, and growth factors to the corresponding receptors, and 
docking of proteases at the cell membrane, as well as in signaling for cell survival 
(Ponta et al 2003). Epithelial CD44 (CD44E) is expressed on the normal 
epithelium of the skin, lung, stomach, intestine, esophagus, bladder, and uterine 
cervix, as well as on normal glandular epithelium, including that of the pancreas, 
bile ducts, sweat glands, prostate gland, mammary glands, salivary glands, and 
thyroid, and in tumors arising from these organs. Mesenchymal cells and all 
types of hematopoietic cells, including erythrocytes, T and B lymphocytes, 
natural killer (NK) cells, macrophages, Kupffer cells, interdigitating cells, follicular 
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dendritic cells, as well as granulocytes, preferentially express CD44s. Therefore, 
CD44s is known also as hematopoietic CD44 (CD44H). The major ligand of 
CD44 is hyaluronic acid (HA, hyaluronan), a linear polymer of repeating 
disaccharide units. It also can bind several other molecules such as collagen, 
fibronectin, fibrinogen, laminin, chondroitin sulfate, mucosal vascular addressin, 
serglycin/gp600, osteopontin (OPN), and the major histocompatibility complex 
class II invariant chain, as well as L-selectin and E-selectin. Normally CD44 does 
not bind to its ligand unless activated by cytokines such as IL-5, tumor necrosis 
factor-α (TNF-α), and interferon-γ (IFN-γ), growth factors such as epidermal 
growth factor (EGF), oncostatin M, and transforming growth factor-β1 (TGF-β1) 
or phorbol ester. Interaction of HA fragments (<200 κDa) with cell surface CD44 
activates cell cycling and proliferation via Ras-MAPK signaling pathway, 
cytoskeleton reorganization, and cell migration via Rho family of proteins, as well 
as maintenance of cell survival via PI3K and NF-κB signaling pathways. As all 
these functions may generate constitutive oncogenic signals leading to 
uncontrolled cell growth and invasive cell migration, CD44 is usually associated 
with malignant tumors. In ovarian cancer, SKOV3 cells demonstrate HA-
dependent/CD44-specific HER2 and c-Src activation to promote cell growth and 
acquisition of the migratory phenotype (Naor et al 2002). CD44, along with other 
molecules such as CD24 and CD133, has been used to identify breast cancer 
stem cells (Al-Hajj et al 2003), pancreatic cancer stem cells (Li et al 2007), and 
prostate cancer (Collins et al 2005). 
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  CD117 is a transmembrane tyrosine receptor kinase encoded by the c-kit 
proto-oncogene. The CD117 ligand is the stem cell factor, an important 
hematopoietic regulator. CD117+ ovarian cancer cells demonstrate the ability of 
self-renewal, differentiation, tumor initiation and chemoresistance (Luo et al 
2011). CD117 combined with CD133 are used to identify CSCs in oral squamous 
cell carcinomas (Margaritescu et al 2011). 
CD133 (Prominin-1), a 120 kDa glycosylated protein containing five 
transmembrane domains was identified initially by the AC133 monoclonal 
antibody, which recognizes a CD34+ hematopietic stem and progenitor cell 
population (Yin et al 1997). Unlike CD44 and CD117, the biological function of 
CD133 is unclear. Recent studies have shown that CD133 expression is not 
limited to primitive blood cells, but is detectable in non-hematopoietic tissues as 
well. CD133 alone has been used as a CSC marker for brain tumors (Singh et al 
2004), liver cancer (Suetsugu et al 2006) (Yin et al 2007), colon cancer (O'Brien 
et al 2007) (Ricci-Vitiani et al 2007), lung cancer (Eramo et al 2008) and ovarian 
cancer (Curley et al 2009). CD133 together with ALDH1 have been used to 
identify HSC (Hess et al 2006), liver cancer stem cells (Ma et al 2008) and 
ovarian cancer stem cells (Silva et al 2011). In ovarian cancer, ALDH+/CD133+ 
cells showed increased proliferation in vitro and in vivo compared to 
ALDH+/CD133- cells, and as few as 11 ALDH+/CD133+ cells could initiate 
tumors in mice. 
Aldehyde dehydrogenase (ALDH) catalyzes the irreversible oxidation of 
aldehydes to corresponding acids (Yoshida et al 1998). High ALDH expression 
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and activity is detected in stem and progenitor cells of various lineages including 
hematopoietic (Storms et al 1999) (Hess et al 2004), endothelial and 
mesenchymal (Gentry et al 2007), neural (Corti et al 2006), mammary (Ginestier 
et al 2007), colon (Huang et al 2009) and lung cancer (Jiang et al 2009). The 
ALDH+ population cells showed increased tumorigenesis and chemoresistance. 
It is believed that ALDH1 catalyzes the conversion of retinol (vitamin A) to 
retinoic acid and thus it can maintain hematopoietic stem cell (HSC) homeostasis 
(Douville et al 2009). However, retinoic acid acts to promote cell differentiation 
and only inhibition of ALDH and retinoid signaling can induce the self-renewal 
ability of HSC (Chute et al 2006). Penumatsa et al reported that ALDH1 
expression is significantly reduced in malignant serous ovarian cancer compared 
to normal ovaries and benign tumors (Penumatsa et al 2010). Another study of 
442 OC patients with long-term follow-up showed that high levels of ALDH1 
expression were observed in 19% of the ovarian carcinoma samples, which 
correlated with endometrioid adenocarcinoma, early-stage disease, complete 
response to chemotherapy, low serum CA125 level and favorable survival 
(Chang et al 2009). Therefore, ALDH1 expression and function in the ovarian 
cancer may be different from breast, lung or colon cancer. Indeed, ALDH1 may 
serve as a marker to identify stem/progenitor cells in tissues where ALDH1 
expression is limited (such as breast) or weak (such as colon). However, for the 
tissues with wide and strong expression of ALDH1 (such as liver and pancreas), 
ALDH1 may not be able to serve as a stem cell marker (Deng et al 2010).  
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Some other proteins have been reported as ovarian cancer stem cell 
markers, such as CD24 (Gao et al 2010), Lin28/Oct4 (Peng et al 2010),  
CD44/MyD88 (Alvero et al 2009), side population (Szotek et al 2006), and label 
retaining (Szotek et al 2008). Given the complexity of different histotypes and 
origins of ovarian cancer, and the heterogeneity of tumors, combination of 
several candidate markers may be necessary to yield the correct stem cell 
population.  
 
1.6 Reseach Objective 
Ovarian cancer is a highly metastatic disease. About 60% cases are 
diagnosed at advanced stage, when the tumor has already spread beyond the 
ovaries. Although most patients respond well to initial debulking surgery and 
chemotherapy, 70% patients with advanced disease suffer recurrence and 
chemoresistance and ultimately die of the disease. Thus, understanding the 
molecular mechanisms regulating ovarian cancer metastasis and 
chemoresistance may provide new targets for more efficient treatment of ovarian 
cancer. 
Our laboratory has previously reported that TG2 is overexpressed in 80% 
of ovarian cancers but not in the normal ovarian surface epithelium, and 
overexpressed TG2 enhances ovarian cancer peritoneal dissemination. As a 
calcium-dependent enzyme which catalyzes intermolecular covalent cross-linking 
of proteins, the function of TG2 in cancer progression is unclear. The goal of this 
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study was to understand how TG2 is upregulated in ovarian cancer and how it 
contributes to ovarian cancer progression.  
Preliminarily I found that TG2 expression level correlates with a 
mesenchymal morphology of ovarian cancer cells. This led to the general 
hypothesis that TG2 induces EMT, a critical process in tumor metastasis, to 
promote ovarian cancer progression. Three specific aims were proposed to test 
this hypothesis.  
Aim 1: To identify the mechanism by which TG2 is overexpressed in 
ovarian cancer. In this specific aim, I tested whether TGF-β, the well-known EMT 
and metastasis inducer and a cytokine abundantly secreted in ovarian cancer 
ascites, increases TG2 expression in ovarian cancer. Further, I investigated the 
signaling pathways involved in this upregulation.  
Aim 2: To determine the mechanism by which TG2 promotes ovarian 
cancer metastasis. In this specific aim, I tested whether TG2 can induce EMT by 
regulation of E-cadherin expression in ovarian cancer cells. As EMT is linked to 
CSCs, I also tested whether TG2 can promote ovarian cancer progression by 
modulating ovarian CSCs homeostasis.  
Aim 3: To delineate the role of TG2 in ovarian cancer chemoresistance. In 
this specific aim, I tested whether TG2 protects ovarian cancer cells from 
apoptosis induced by cisplatin, the first line of chemotherapy for ovarian cancer 
patients. I further investigated the mechanism implicated in TG2 induced 
chemoresistance. 
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Overall, this study aimed to uncover the role of TG2 in ovarian cancer 
metastasis and chemoresistance, which are the major contributors to ovarian 
cancer related death. Therefore, this study will elucidate the progression of 
ovarian cancer and provide insight into TG2 implication in OC pathogenesis that 
can be ultimately targeted for treatment.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Chemicals and reagents 
 Human TGF-β1 was from R&D Systems (Minneapolis, MN), TGF-β 
receptor I kinase inhibitor was from Calbiochem (La Jolla, CA) and TGF-β 
receptor I kinase inhibitor SD-208 was from Scios Inc. (Fremont, CA, USA). 
Cisplatin and methylthiazolyldiphenyl-tetrazolium bromide (MTT) were purchased 
from Sigma (St. Louis, MO). TG2 enzyme inhibitor, KCC009, was provided by 
Alvine Pharmaceuticals (San Carlos, CA). The antibody against TG2 was from 
Neomarkers (Fremont, CA); antibodies against phospho-Smad2, phospho-TAK1,  
phospho-p38, phospho-JNK1/2, phospho-Akt, Smad2/3, TAK1, p38, JNK1/2, 
phospho-FAK, phospho-Ser473Akt, N-cadherin, and E-cadherin were from Cell 
Signaling Technology (Danvers, MA); antibodies against TGF-β1 receptor I and 
II, Smad7 and Caspase-9 P35 were from Santa Cruz Biotechnology (Santa Cruz, 
CA); neutralizing TGF-β antibody (MAB1835) was from R&D (Minneapolis, MN); 
antibodies against cytochrome c and hILP/XIAP were from BD Bioscience (San 
Jose, CA); anti-GAPDH was from Biodesign International (Saco, ME) and anti-β-
actin was from Sigma. 
 
2.2 Human ovarian tumors and ascites specimens 
Studies using human specimens were approved by the IU Institutional 
Review Board; all specimens being de-identified. Tumors were obtained at 
debulking surgery and the diagnosis of OC was verified. All tumors were serous 
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papillary. Ten samples of OC malignant ascites and three samples of 
inflammatory parapneumonic pleural fluid were obtained from the IU Tissue Bank. 
 
2.3 Cell lines and primary cultures 
 Human OC cell lines SKOV3, Hey, OV90, and IGROV-1 were from the 
American Type Culture Collection (ATCC).  The mesothelial cell line LP9 was 
from Dr. Y. Xu (Indiana University, IU). Normal ovarian surface epithelial (NOSE) 
cells were from Dr. R. Bigsby (IU) and were generated from normal human 
ovaries obtained during surgery from nonmalignant gynecological disorders. 
Pieces of an ovary were cultured as explants in medium containing 1:1 MCDB 
105 (Sigma) and M199 (Cellgro, Herndon, VA) supplemented with 20% heat-
inactivated fetal bovine serum (FBS, Cellgro) and 1% antibiotics (100 U/ml 
penicillin and 100 μg/ml streptomycin). Once cells grew out from the specimen, 
the tissue was transferred to another culture dish. After cells reached 
approximately 50% confluence, they were passaged and grown in a medium 
supplemented with 10% FBS (Wang et al 2008). The immortalized cell line 
C272/hTert/E7 was derived from CSOC (Cedars Sinai ovarian carcinoma, 
epithelial cells derived from EOC) culture by transducing human telomerase 
hTERT and the human papilloma virus E7 gene products (Gillan et al 2002). 
OVCA cells are primary cultures obtained from OC malignant ascites or from 
disaggregated human ovarian tumors.  All cells were cultured in media containing 
1:1 MCDB 105 and M199 supplemented with 10% FBS, penicillin (100 units/ml), 
and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 atmosphere. 
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2.4 Cell proliferation 
Cell proliferation was assayed by methylthiazolyldiphenyl-tetrazolium 
bromide (MTT) and BrdU assays. In brief, after treatment, cells were incubated 
with MTT (200 μl of 1 mg/ml in RPMI) for 4 h. The formazan crystals formed were 
solubilized in 200 μl acidified isopropanol (0.04 N HCl final) containing 1% Triton 
X-100 for 10 min, and the optical density was measured with an ELISA plate 
reader (SpectraMax 190, Molecular Devices, Sunnyvale, CA) at 570 nm. In 
addition, an enzyme-linked immunosorbent assay colorimetric method based on 
measurement of BrdU incorporation into DNA (Roche Diagnostics, Penzberg, 
Germany) was used to assess cell proliferation. In brief, after cisplatin treatment, 
cells were incubated with BrdU (10 μM) for 3 h, and fixed. Cells were 
subsequently treated with a peroxidase-labeled anti-BrdU antibody for 90 min 
and the colorimetric reaction was developed with a tetramethyl-benzidine-based 
substrate. The reaction product was measured at 370 nm. All assays were 
performed in quadruplicate and were repeated twice in independent conditions. 
Data are presented as means ± SEM.  
 
2.5 Chromatin immunoprecipitation (ChIP) assay 
To detect the interaction between Smads and the TG2 promoter, ChIP 
assays were performed by using a kit from Millipore, Smad4 (Abcam) and 
phospho-Smad3 (Cell Signaling) antibodies. In brief, after crosslinking with 
formaldehyde, DNA from C272/hTert/E7 cells treated or not with TGF-β1 was 
immunoprecipitated with Smad4 or pSmad3 antibodies. Bound DNA was purified 
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and PCR amplified with primers flanking the -191 to -840 TG2 promoter regions.  
Ten putative SBEs were identified within this region by a bioinformatics tool 
PROMO (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo). As the exact SBE 
was not known, 4 pairs of primers, each encompassing 200bp domains were 
designed to cover this region (Table 2, Figure 7).  PCR with primers covering the 
-269 to -479 promoter fragments yielded a positive signal, indicating that the 
Smad complex bound to this region. Chromatin immunoprecipitated with Smad4 
or with pSmad3 antibody was amplified with primers designed for an upstream 
region (800-1000): TGC CAT GTG TTA GGA GCA CAA G (F), ATG CCT AGA 
ATC CCA GCG TTA GAG(R), as the negative control.  Another negative control 
was DNA immunoprecipitated with IgG and subjected to PCR amplification. For 
real time quantitative PCR detection of bound DNA, SYBR-Green master mix 
was used on an ABI Prism 7900 platform, and percentage of input was 
calculated. For negative control, chromatin immunoprecipitated with normal 
mouse IgG was amplified with primers specific for TG2 promoter region. For 
positive control, chromatin immunoprecipitated with anti-RNA polymerase II was 
amplified with primers specific for human GAPDH. 
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Table2: Primers designed for ChIP assay. 
Primer # Regions covered Primer sequence 
1 1111-1312 
(-688 to -889) 
F: GGT GAG ATC GGA GGA TTA TCT G 
R: AGA CCT CCT AGA CAC CAA TG 
2 1521-1731 
(-269 to -479) 
F: ATC TCC ACA GCC CTG TCT TG 
R: GCA GCA CCC TCA TAG AAA C 
3 1390-1732 
(-268 to -610) 
F: GCT GTG TCA GGC TGT ATC TAT GTC 
R: ACG CAG CAC CCT CAT AGA AAC 
4 1716-2034 
(34 to -284) 
F: CTA TGA GGG TGC TGC GTG TG 
R: GGC TGC GGT GAC TCT GAT AC 
 
 
 
Figure 7: Schematics of primers designed for ChIP assay. Ten putative SBEs 
were identified within this region by a bioinformatics tool PROMO in the region 
from -191 to -840 of TG2 promoter. 4 pairs of primers, each encompassing 
200bp domains were designed to cover this region. 
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2.6 Clonogenic assay 
OC cells were seeded in six-well plates at a density of 100 cells per well. 
Triplicate wells were treated with 1, 2 and 5 μM cisplatin for 48 h after which the 
media was changed. Cells were allowed to grow for 10 days until visible colonies 
were formed. The colonies were fixed and stained with Hema 3 stain (Fisher) and 
counted. The number of colonies formed after treatment with cisplatin was 
expressed as a percentage of untreated controls (relative colony formation). Data 
are presented as means ± SDs.  
 
2.7 Enzyme-linked immunosorbent assay (ELISA) 
An ELISA assay (R&D) measured TGF-β1 concentrations in the 
conditioned media (CM) of OC or NOSE cells and in malignant OC ascites or 
pleural fluid from non-malignant conditions, following the manufacturer’s protocol. 
In brief, 50 μL per well of standard, control, or activated sample were incubated 
with a monoclonal antibody specific for TGF-β1 coated on the polystyrene 
microplate for 2 hours at room temperature, followed by incubation with 100 μL 
polyclonal antibody against TGF-β1 conjugated to horseradish peroxidase for 2 
hours at room temperature, then with 100 μL substrate (hydrogen peroxide with 
the chromogen tetramethylbenzidine) for 30 minutes at room temperature, with 4 
times wash with was buffer between all steps. 100 μL stop solution (hydrochloric 
acid solution) was added before reading the plate at 450 nm within 30 minutes. 
TGF-β1 concentrations were calculated according to the standard curve. 
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2.8 Flow Cytometry 
 Single cell suspension in PBS containing 1% FBS ( about 106cell/100uL) 
were incubated with FITC-conjugated anti-CD44 (BD Biosciences), APC-
conjugated anti-CD117 (BD Biosciences), FITC- mouse IgG κ isotype control and 
APC-mouse IgG κ isotype control (BD Bioscience) at 4°C for 30-40 minutes in 
dark. Labeled cells were washed with PBS containing 1% FBS, fixed in PBS 
containing 1% paraformaldehyde, and detected on a BD FACS Calibure flow 
cytometer according to the manufacturer’s procedure. Flow data were analyzed 
using BD CellQuest software. Ten thousand events were accumulated for each 
analysis. Three independent readings were obtained from separate experiments, 
and data were averaged for statistical analysis.  
 
2.9 Fluorometric caspase-3 and -9 assays 
Caspase-3 activity was measured in cell lysates by a fluorescence-based 
assay (Apo-ONE Homogeneous Caspase-3/7 Assay, Promega) following the 
manufacturer's protocol. Sequential cleavage and removal of the Asp-Glu-Val-
Asp peptides from the profluorescent substrate (Z-Asp-Glu-Val-Asp-R100) by 
active caspase-3 releases the fluorescent rhodamine product, which can be 
measured by a SpectraMax M5 Microplate Reader, at an excitation wavelength 
of 485 nm and an emission wavelength of 530 nm. Recombinant active caspase-
3 (Chemicon) was used as a positive control and denominator for analysis. 
Likewise, caspase-9 activity was measured in cell lysates using a fluorescence-
based assay (BioVision, Mountain View, CA) according to the manufacturer's 
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protocol. The assay is based on detection of cleavage of substrate LEHD–7-
amino-4-trifluoromethyl coumarin (AFC). LEHD–AFC emits blue light; upon 
cleavage of the substrate by active caspase-9, free AFC emits yellow–green 
fluorescence which can be quantified using a SpectraMax M5 Microplate Reader. 
Comparison of the fluorescence of AFC from an experimental sample with an 
uninduced control allows determination of the fold increase in caspase-9 activity. 
The fluorescent units for caspase-3 and -9 were normalized to the amount of 
protein measured for each sample using the Bradford method.  
 
2.10 Gene reporter assay 
A Dual-Luciferase Reporter Assay (Promega, Madison, WI) was 
performed to quantify TG2 and NF-κB-dependent promoter activities in SKOV3 
and C272 hTert/E7 cells. In brief, cells were transiently co-transfected with the 
experimental reporter plasmid and control renilla plasmid at 10:1 ratio using 
DreamFect Gold transfection reagent (OZ Biosciences). Luminescence was 
measured with a TD-20/20 luminometer (Turner Biosystems, Sunnyvale, CA) and 
normalized to the internal control renilla. The experiments were performed in 
duplicate and repeated in independent conditions.   
 
2.11 Immunoblotting 
Cells were lysed in radioimmunoprecipitation assay buffer (RIPA, pH 7.5 
50mM Tris-HCl, pH 7.0 1mM EDTA, 150mM NaCl, 1% Triton X-100, 1% 
deoxycholic acid ) containing protease inhibitors leupeptin (1 µg/mL), aprotinin (1 
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µg/mL), phenylmethylsulfonyl fluoride (PMSF, 400 µM), and sodium 
orthovanadate (Na3VO4, 1 mM). Cell lysates were sonicated briefly and subjected 
to centrifugation at 14,000 rpm for 15 min at 4°C to sediment particulate material.  
Protein concentration was measured by the Bradford method (BioRad). Equal 
amounts of protein were mixed with Laemmli sample buffer (BioRad) containing 
5% 2-Mercaptoethanol (Sigma), separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) using 1x Tris-glycine buffer (25 
mM Tris base, 190 mM glycine) containing 0.1% SDS, and then electroblotted 
onto polyvinylidene difluoride membranes (PVDF, Millipore, Billerica, MA) using 
1x Tris-glycine buffer with 20% methanol. Proteins on the membrane were 
visualized with Ponceau Red (Sigma) to check if proteins were loaded equally or 
transferred to the membrane successfully. To prevent non-specific background 
binding of primary and/or secondary antibodies to the membrane, the membrane 
was blocked with 5% non-fat milk in 1xTris Bufferred Saline containing Tween 20 
(TBST) for 1 hour at room temperature. The membranes were incubated with 
specific primary antibody overnight at 4°C with gentle rocking, then washed thrice 
with 1xTBST, 5 minutes per wash to remove unbound primary antibody. The 
membranes were then incubated with specific horseradish peroxidase (HRP)-
conjugated secondary antibody for 1 hour at room temperature, followed by 
thrice wash with 1xTBST. Antigen-antibody complexes were visualized using the 
enhanced chemiluminescence (ECL) detection system (Amersham Biosciences, 
Piscataway, NJ).  
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2.12 Immunofluorescence assay 
OC cells were plated on fibronectin-coated chamber slides (BD 
Biosciences) and allowed to adhere. 24 hours later, cells were washed with 
1xPBS, then fixed in 4% paraformaldehyde for 10 minutes, washed with 1xPBS 
for 5 minutes, and permeabilized with 0.2% Triton X-100 for 5 minutes, washed 
again with 1xPBS for 5 minutes. After blocking at room temperature for 1 hour 
with 3% goat serum in 1xPBS, cells were incubated with primary antibodies, 
rabbit-anti–E-cadherin (1:200), Cy5-labeled anti-vimentin (Sigma, 1:200), and 
isotype-specific IgG (control) in blocking buffer at room temperature for 1 hour, 
washed thrice with 1xPBS, 10 minutes per wash. The cells were then incubated 
with Alexa Fluor 488–labeled anti-rabbit secondary antibody (1:1,000; Molecular 
Probes) in blocking buffer at room temperature for 1 hour, washed thrice with 
1xPBS, 10 minutes per wash. Images were captured using a Zeiss LSM 510 
confocal microscope system under UV excitation at 488 nm (Alexa Fluor 488), 
630 nm (Cy5), and 360 nm [4, 6-diamidino-2-phenylindole (DAPI, Vectashield, 
Vector Laboratories)], and analyzed with Zeiss LSM software. 
 
2.13 Immunohistochemistry 
A tissue microarray from Pantomics (San Francisco, CA, USA) including 
30 human epithelial ovarian tumors arrayed in duplicates was immunostained for 
pSMAD3 and TG2. In brief, the slides were heated at 56°C for 1 hour to melt the 
paraffin, then deparaffinized by consecutive washes with xylene, then rehydrated 
by graded washes with ethanol and water. 3% hydrogen peroxide was used to 
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quench the endogenous peroxidase activity. After antigen retrieval with 0.01M 
sodium citrate, the slides were blocked with 3% goat serum in TBS and 
incubated with primary antibody against TG2 (CUB 7402, NeoMarkers, 1:200, 1 
hour at room temperature ) and pSmad3 (Abcam, 1:50, 4°C overnight). The 
antigen-antibody complex formation was detected with the avidin/biotin system 
(LSAB2 kit, DAKO, Hamburg, Germany). Slides were stained with 3, 3′-
diaminobenzidine and counterstained with hematoxylin. Negative controls were 
run in parallel, with omission of the primary antibody. Staining was graded from 0 
(no staining) to 3+ (strong staining). Immunoreactivity was recorded only if noted 
in more than 15% to 20% of tumor cells. An H-score was calculated as a product 
combining both intensity and percentage of cells staining, using the following 
formula: H-score= (% at 0) * 0 + (% at 1+) * 1 + (% at 2+) * 2 + (% at 3+) * 3. 
Tumors were classified as positive or negative if H score was > or < median 
score, respectively. The H-score of TG2 and pSmad3 staining were then used to 
calculate the correlation of TG2 and pSmad3 expression in human ovarian tumor 
sample by Fisher's exact test. 
 
2.14 In situ TG2 activity assay 
The assay was performed to determine the incorporation of 5-(biotinamido) 
pentylamine (BPA, Pierce) into proteins, as previously described (Zhang et al 
1998). In brief, cells were treated with TGF-β1 or vehicle control for 48h, and 
incubated with 2 mM BPA for 1 hour, 5mM EDTA or 5mM CaCl2 for 1 hour before 
harvesting. Cells were washed with cold PBS once and collected in 
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homogenizing buffer (pH 7.5 50mM Tris-HCl, 150mM NaCl, and 1mM EDTA) 
with protease inhibitors. Cell lysates were sonicated briefly on ice and protein 
concentration was measured using Bradford assay. Equal amounts of protein 
were run on 8% SDS gels (100v, 2 hours), and semi-dry transferred to 
nitrocellulose membrane (20v, 40 minutes). The membrane was blocked 2 hours 
at room temperature with 5% BSA, 0.05% SDS, 0.01% NP40 in BBS (100mM 
boric acid, 20mM sodium borate, 80mM NaCl), then incubated with HRP-
conjugated streptavidin (1:200, Pierce) in 1% BSA, 0.05% SDS, 0.01% NP40 in 
BBS for 2 hours at room temperature. The blot was then washed thrice with1% 
BSA, 0.05% SDS, 0.01% NP40 in BBS, 10 minutes per wash, followed by a 
quick rinse with distilled water, then developed with ECL. TG2 activity is 
evidenced by BPA labeling of the cellular proteins on the blot, shown as the black 
bands on the blots. 
 
2.15 Introperitoneal ovarian xenograft model 
3 × 106 SKOV3 cells stably transfected with AS-TG2 or pCDNA3.1 vector 
were injected i.p. in 7–8 weeks old female nude mice from Harlan (Indianapolis, 
IN). Treatment with SD208 (60mg/kg daily) or vehicle control began 1 week after 
i.p. implantation via gavage and was continued for 5 weeks. Each of the four 
experimental groups consisted of four animals. Six weeks after i.p. injection, mice 
were euthanized, peritoneal implants were counted. Tumors were measured bi-
dimensionally if >5mm and tumor volume was calculated according to the 
formula LxW2/2, where L is length and W is width. Acumulative tumor volume 
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was calculated by adding the volumes of dominant tumors for each animal. Large 
tumor masses were harvested and frozen in liquid nitrogen for future experiments. 
Student’s t test was used to compare the volumes and numbers of peritoneal 
implants between any two animal groups. Experiments were approved by the IU 
Animal Care and Use Committee. 
 
2.16 Isolation and detection of ovarian cancer stem cells 
Fresh tumor samples were minced and digested in serum-free Dulbecco's 
modified Eagle's medium/F12 media (Invitrogen, Carlsbad, CA, USA) containing 
collagenase and hyaluronidase (Sigma-Aldrich). The resulting single cell 
suspension was filtered through a 40-μm cell strainer and red blood cells were 
removed with Histopaque-1077 (Sigma-Aldrich). Cells dissociated from tumors or 
OC cell lines were labeled with fluorescein isothiocyanate-conjugated anti-CD44 
and antigen-presenting cell-conjugated anti-CD117 and sorted using a FACS-
Aria flow cytometer (BD Biosciences, San Jose, CA, USA). Quantification of the 
CD44+/CD117+ population in tumor cells or OC cell lines was performed on 
FACSCalibur (BD Biosciences). 
 
2.17 Migration Assay 
A migration assay was done in a modified Boyden chamber method using 
6.5-mm-diameter, 8.0-μm pore size polycarbonate membrane transwell inserts in 
a 24-well plate (Corning). To assess directional migration, the lower surfaces of 
the transwell membrane were coated with 50 μg/mL fibronectin or with 0.01% 
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type I collagen (Sigma). SKOV3 cells stably transfected with AS-TG2 or vector 
were serum starved for 18 h and then plated in the upper well at a concentration 
of 2 × 105 in 100 μL of serum-free medium. After 4 h of incubation at 37°C in a 
CO2 incubator, the cells on the upper surface of the membrane were wiped off 
with a cotton swab. The cells on the lower surface of the transwell were stained 
with HEMA3 stain (Fisher) and counted at ×200 magnification. Cells were 
counted in five high-power fields (HPF) in duplicate experiments. Results are 
expressed as mean number of migrating cells ± SE. A similar experiment was 
done using serum-free conditioned medium from cells stably transfected with AS-
TG2 or pcDNA3.1 as cell attractant in the lower chamber of the transwell. 
 
2.18 Matrigel Invasion Assay 
Invasion assay was done by using two-dimensional and three-dimensional 
cell cultures in a Matrigel matrix (BD-Biosciences). Briefly, 2.5 × 104 cells 
suspended in 50 μL of cell culture medium were seeded onto solidified Matrigel 
in 24-well plates as a monolayer (two-dimensional model) or mixed and 
embedded within the matrix (three-dimensional model). After incubation at 37°C 
for 24 to 48 hours, invasive cells adhered to the surface of the gel and spread to 
form networks (two-dimensional model) or degraded and invaded into the gel 
(three-dimensional). These were observed under an inverted microscope and 
photographed live. The experiments were done in duplicate and repeated in 
independent conditions.  
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2.19 Reverse transcription-Polymerase chain reaction (RT-PCR) and 
quantified RT-PCR (qRT-PCR) 
RNA was extracted with RNA STAT-60 reagent (Tel-Test Inc., 
Friendswood, TX). In brief, cells were homogenized with RNA STAT-60 (1 ml per 
5-10 x 106 cells) and RNA was extracted from the upper layer with 0.2 volume of 
chloroform, precipitated with 0.5 volume of isopropanol and washed with 75% 
ethanol. RNA was reverse-transcribed using iScript cDNA synthesis kit (Bio-Rad). 
In brief, 1μg RNA was transcribed by 1 μL MMLV-derived reverse transcriptase in 
a 20μL reaction system at 42°C for 30 minutes, using a blend of oligo dT and 
random hexamer primers, followed by incubation at 85°C for 5 minutes to heat-
inactivate the reverse transcriptase. The cDNA product was then used for semi-
quantified PCR or qPCR.  
The PCR reactions used Taq polymerase (Promega, Madison, WI) and 
the primers listed in Table 3. For qPCR, 1uL of the cDNA product was amplified 
in a 20uL reaction system with FastStart Universal Probe Master (ROX) (Roche) 
on an ABI Prism 7900 platform (Applied Biosystems), using specific primers 
(900nM) and probes (250nM) (Table 3). At the end of the PCR reaction, a 
melting curve was generated and the cycle threshold (Ct) was recorded for the 
target genes and for GAPDH. Relative expression of gene of interest was 
calculated as ΔCt, measured by subtracting the Ct of the reference gene from 
that of the control. Results are presented as mean ± SD of replicates. Each 
experiment was done in duplicates and repeated in independent conditions. 
Relative mRNA expression levels were normalized to GAPDH. 
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Table 3: Primers used for PCR reaction. 
Target gene Primers 
Snail-1 F: ACC CCA CAT CCT TCT CAC TG 
R: TAC AAA AAC CCA CGC AGA CA 
Slug F: CTT TTT CTT GCC CTC ACT GC 
R: ACA GCA GCC AGA TTC CTC AT 
Snail-3 F: AAA TCA ATG GTG CCT GCT CT 
R: GGC TGT CTT TGA GGG GTA CA 
Zeb-1 F: TGC ACT GAG TGT GGA AAA GC 
R: CTT GCC ACA CTC TGT GCA TT 
Zeb-2 F: CGC TTG ACA TCA CTG AAG GA  
R: CTT GCC ACA CTC TGT GCA TT 
Twist-1 F: ACC ATC CTC ACA CCT CTG CAT TCT 
R:TGC AGG CCA GTT TGA TCC CAG TAT 
Twist-2 F: AGC AAG AAG TCG AGC GAA GA 
R: CAG CTT GAG CGT CTG GAT CT 
GAPDH F: GAT TCC ACC CAT GGC AAA TTC C 
R: CAC GTT GGC AGT GGG GAC 
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Table 4: Primers and probes used for qPCR. 
Target gene Primers Probe 
TG2 F:AGG GTG ACA AGA GCG AGA TG 
R: TGG TCA TCC ACG ACT CCAC 
86 
GAPDH F: AGC ACA TCG CTC AGA CAC 
R: GCC CAA TAC GAC CAA ATC C 
60 
Nanog F: GAT GCC TCA CAC GGA GAC T 
R: TTT GCG ACA CTC TTC TCT GC 
31 
Sox2 F: TGC TGC TCT TTA AGA CTA GGA C 
R: CCT GGG GCT CAA ACT TCT CT 
35 
Oct3/4 F: CTT CGC AAG CCC TCA TTT C 
R: GAG AAG GCG AAA TCC GAA G 
60 
Zeb-1 F: GCC AAC AGA CCA GAC AGT GTT 
R: TTT CTT GCC CTT CCT TTC TG 
68 
Zeb-2 F: AAG CCA GGG ACA GAT CAG C 
R: GCC ACA CTC TGT GCA TTT GA 
68 
Snail F: GCT GCA GGA CTC TAA TCC AGA 
R: ATC TCC GGA GGT GGG ATG 
11 
Slug F: TGG TTG CTT CAA GGA CAC AT 
R: GTT GCA GTG AGG GCA AGA A 
7 
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2.20 Solid phase adhesion assay 
Exponentially growing cells were detached from culture plates by 
trypsinization and labeled with calcein acetoxymethylester (calcein AM; 2 μM; 
Molecular Probes) for 20 min. After washing, cells were resuspended in serum-
free medium. Equal numbers of cells (4 × 104 per well) were seeded into 96-well 
plates precoated with 5ug/mL fibronectin (Sigma) and blocked with bovine serum 
albumin (1% w/v). After 1 h of incubation at 37°C, the plate was immersed into 
PBS containing 1 mM MgCl2 to remove non-adherent cells. The number of 
adherent cells was measured in a fluorescence plate reader (Applied 
Biosystems, Foster City, CA,) at an excitation wavelength of 485 nm and an 
emission wavelength of 530 nm. All experiments were done in quadruplicate and 
repeated twice. 
 
2.21. Spheroid culture 
To induce formation of cellular spheroids, OC cells were seeded at a 
concentration of 1000 cells/mL in serum-free Dulbecco's modified Eagle's 
medium/F12 supplemented with 5 µg/mL insulin (Sigma), 20 ng/mL human 
recombinant epidermal growth factor (EGF; Invitrogen), 10 ng/mL basic fibroblast 
growth factor (bFGF; Invitrogen), and 0.4% bovine serum albumin (BSA; Sigma) 
in ultra-low attachment plates (Corning, Corning, NY) and allowed to form 
spheroids over 10–14 days. Spheroids were counted in 10 high-power fields 
(HPF) in duplicate experiments. Results are expressed as mean number of 
spheroids number ± SD. 
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  2.22 Transfection and transduction 
Stable knock-down of TG2 was achieved by transfection of an antisense 
construct (AS-TG2) or by transducing lentiviral particles containing shRNA 
targeting TG2 (Sigma). The AS-TG2 plasmid was a generous gift from Professor 
Janusz Tucholski, of University of Alabama. To generate SKOV3 AS-TG2 cells, 
an anti-sense construct (AS-TG2) cloned into pcDNA3.1 vector was transfected 
in SKOV3 cells using Fugene transfection reagent (Roche, Indianapolis, IN).  As 
control, cells were transfected with pcDNA3.1 vector, carrying the G418 
resistance gene. Stable transfected clones were established by selection with 
G418 (Sigma). Knock-down of TG2 in selected clones was demonstrated by 
Western Blot analysis. To generate IGROV-1 shTG2 cells, 3 packaging vectors 
(pMDL, pRSV, pMDG) and Sh RNA (scrambled Sh RNA control shc 002 (Sigma) 
and Sh-TG2 41, 43 (Sigma) were used to transfected packaging HEK293 cells 
with DreamFect (OZ Biosciences, Marseille, France). Virus were harvested from 
HEK293 cell supernatant and transduced into IGROV-1 cells with 8ug/mL 
polybrene (Sigma). Pooled stable transduced clones were established by 
selection with puromycin (Sigma). Knock-down of TG2 in selected clones was 
demonstrated by Western Blot analysis.  
Stable overexpression of wild type TG2, TG2 fibronectin binding domain 
tTG 1-140, TG2 enzymatic mutant C277S, and TG2 GTPase mutant R580A in 
OV90 cells, an ovarian cancer cell line which doesn’t express TG2, was achieved 
by transfection of pcDNA3.1 TG2 construct or by transduction of bicistronic 
retroviral vector pQCXIP (BD Biosciences, San Jose, CA). To transfect the 
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pcDNA3.1 TG2 construct, OV90 cells in the logarithmic phase of growth were 
transfected with wild-type TG2 cloned into the pcDNA3.1 vector using Fugene 
(Roche Applied Science). Stable transfected clones were established by 
selection with G418 (Sigma) and expression of TG2 was demonstrated by 
Western Blot analysis. For transduction of pQCXIP constructs, wild type TG2, 
tTG 1-140, TG2 C277S, and TG2 R580A were subcloned from pcDNA3.1 
constructs to pQCXIP constructs, and transfected into packaging Amphophenix 
cells with DreamFect (OZ Biosciences). Virus was harvested and transduced into 
OV90 cells with 8ug/mL polybrene (Sigma). Pooled stable transduced clones 
were established by selection with puromycin (Sigma) and expression levels of 
TG2 and mutants were demonstrated by Western Blot analysis. The constructs 
pcDNA3.1 tTG10-140,  pcDNA3.1 TG2 C277S, and pcDNA3.1 TG2 R580A were 
kind gifts from Dr. Belkin (Maryland University, MD) (Hang et al 2005), Dr. 
Cerione (Cornell University, NY), and Dr. Johnson (Rochester University, NY) 
(Ruan et al 2008) respectively. 
To overexpress Zeb1 and reconstitute NF-κB and Akt activities in SKOV3 
cells stably transfected with AS-TG2 or vector, full-length Zeb1 cDNA, 
constitutively active p65 subunit of NF-κB (p65NLS50) which has less affinity for 
IκBα by replacing the nuclear localization signal (NLS) of p65 with the NLS of 
p50, and a constitutively active form of Akt that lacks the pleckstrin homology 
domain were transferred by retroviral infection and pooled colonies were 
selected. These constructs cloned in pQCXIP were generous gifts from Dr. H. 
Nakshatri (Indiana University, IN).  
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Transient transfection of siRNAs targeting Smad2/3 (Cell Signaling), TAK-
1 (Thermo Scientific Dharmacon, Lafayette, CO), p38 (Cell Signaling), JNK2, 
p65, Zeb1 or scrambled siRNA (Dharmacon) were performed by using 
DreamFect (OZ Biosciences). 
 
2.23 TdT-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) 
assay 
TdT (terminal deoxynucleotidyl transferase)-mediated deoxyuridine 
triphosphate nick-end labeling assay (Chemicon, Temecula, CA) was utilized to 
quantify cisplatin-induced apoptosis. In brief, after cisplatin treatment, cells were 
fixed in 1% paraformaldehyde in phosphate-buffered saline for 10 min at room 
temperature and then in ethanol:acetic acid (2:1) for 5 min at −20°C. Fixed cells 
were blocked with equilibration buffer for 1 min at room temperature and treated 
with TdT enzyme and anti-digoxingenin conjugate. A mounting medium 
containing 4′,6 -diamidino-2-phenylindole (Vectorshield, Vector Laboratories, 
Burlingame, CA) was used. Cells were viewed by fluorescence microscope and 
counted at high power magnification (×400). Five fields were counted in each of 
the duplicated wells. Data are presented as means ± SEM.  
 
2.24 Analysis of combined drug effects 
Drug synergy was measured using the CalcuSyn software (Biosoft, 
Ferguson, MO). To perform these analyses, we used the data obtained from the 
growth inhibitory experiments, generated isobolograms and measured the 
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combination index (CI) based on the median-effect principle of Chou et al (Chou 
and Talalay 1984). The CI method is a mathematical representation that 
measures two-drug pharmacologic interaction. A CI of 1 indicates an additive 
effect between two agents, a CI <1 indicates synergism, whereas a CI >1 
represents antagonism.  
 
2.25 Statistical analysis 
Comparisons between groups were performed using Student's t-test; 
Fisher's exact test was used to compare immunohistochemistry staining for TG2 
and pSmad3. P-values <0.05 were considered significant. 50% inhibitory 
concentration (IC50) values for inhibition of cell proliferation by cisplatin and 
KCC009 were calculated as the concentration of drugs resulting in a 50% of 
reduction in viable cells compared with untreated controls by MTT or BrdU 
assays. The IC50 values and the combination effect of multiple drugs were 
determined using the Calcusyn software program for Windows (Version 1.2, 
1996; Biosoft, Cambridge, UK).  
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CHAPTER 3: RESULTS 
3.1 TGF-β1 induces TG2 overexpression in OC cells 
3.1.1 TGF-β1 is secreted in OC microenviroment 
First we determined if TGF-β is presented in the OC milieu. As TGF-β1 is 
reported to be the major isoform in OC and OC associated ascitic fluid 
(Abendstein et al 2000, Henriksen et al 1995), we focused our study on TGF-β1. 
To test whether TGF-β1 is secreted by OC cells, an ELISA assay was used to 
quantify TGF-β1 secretion in serum-free conditioned media  from OC cell lines or 
primary OC cells (n=12) and in media conditioned by normal ovarian surface 
epithelial cells (NOSE) (n=3). Higher levels of TGF-β1 were detected in 
conditioned media from OC cells (1203 +/-271pg/mL) compared to NOSE (71+/- 
23pg/mL; p=0.002, Figure 8A), suggesting that TGF-β is secreted in higher 
amounts by malignant cancer cells as opposed to normal ovarian epithelial cells.  
As OC progression leads to accumulation of peritoneal fluid rich in secreted 
proteins, we also measured TGF-β1 secretion in OC associated ascites (n=10) 
compared with benign effusions (n=3). The cytokine was detected in the 
peritoneal OC fluid at higher levels (1719+/-275pg/ml) than in non-malignant 
effusions (387+/-341pg/mL; p=0.004, Figure 8B).  This demonstrates that TGF-
β1 is presented in OC microenviroment, and OC cells are a source of TGF-β1. 
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A.                                                             B. 
 
 
Figure 8: TGF-β1 is secreted in OC microenvironment. A. TGF-β1 measured 
by enzyme-linked immunosorbent assay (ELISA) in serum-free conditioned 
media (CM) of OC (n=12) vs. NOSE cells (n=3, P=0.002). B. TGF-β1 measured 
by ELISA in OC malignant ascites (n=10) vs. non-cancer pleural fluid (n=3, 
P=0.004). 
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3.1.2 TGF-β1 induces TG2 upregulation in OC cells 
Previously our lab reported that TG2 is overexpressed in OC cells in 
association with a metastatic phenotype (Satpathy et al 2007, Satpathy et al 
2009). As TGF-β1 exists in OC microenviroment and promotes OC metastasis 
(Do et al 2008), we tested whether TGF-β1 induces TG2 expression. Several OC 
cell lines and primary OC cells were serum starved for 16 to 24 hours and treated 
with TGF-β1 (5ng/mL) for 24 to 48 hours, and TG2 protein in these cells were 
detected by Western analysis. Increased TG2 expression was observed in 
primary OC cells (OVCA), immortalized C272/hTert/E7 cells, and ovarian cancer 
cell lines: SKOV3, Hey, and IGROV-1 cells treated with TGF-β1 for 24-48 hours 
(Figure 9A). In contrast, TGF-β1 did not augment TG2 expression in normal 
ovarian surface epithelial cells (NOSE), or in the non-transformed mesothelial 
cells LP9 derived from human peritoneum (Figure 9B). Dose-response 
experiments demonstrated that the effects of TGF-β1 on TG2 expression occur 
from concentrations from 0.5ng/mL to 5ng/mL which are physiologically relevant 
concentrations (Figure 10A). The effects of TGF-β1 on TG2 expression were 
more pronounced when cells were cultured on fibronectin mimicking the 
interaction with the ECM (Figure 10B), therefore subsequent experiments used 
FN-coated plates.   
To elucidate why there is a difference in response to TGF-β1 between OC 
cell lines, non-transformed NOSE and LP9 cells, the signaling pathways 
downstream of TGF-β1 were analyzed. Cell surface TGF-β receptor I and II, 
intracellular signal transducers including regulatory Smad2/3 and inhibitory 
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Smad7, and non-Smad pathway signal mediator TAK1 were detected by 
Western analysis in these cells. The results showed that OC cell lines and non-
transformed NOSE and LP9 cells express TGF-β receptors I and II and TAK1 at 
similar levels.  However, Smad2/3 expression levels were slightly lower in NOSE 
and LP9 cells compared to OC cells, while the inhibitory protein Smad7 was 
expressed in NOSE and LP9 cells, but not in all OC cell lines (Figure 11). These 
data reveal that the R-Smads may be more abundant in cancer cells, whereas 
the I-Smad is more abundant in normal cells. 
The Western blot analysis showed that TG2 expression can be 
upregulated by TGF-β1 at protein level. To investigate whether TG2 was induced 
by TGF-β1 at transcriptional level, OC cell lines SKOV3 and C272/hTert/E7 were 
treated with TGF-β1. Total RNA was collected to measure TG2 mRNA level by 
qRT-PCR. Compared with control, the results showed that TGF-β1 induces TG2 
mRNA expression in OC cells (Figure 12A, P<0.05), and this induction can be 
blocked by TGF-β neutralizing antibody (Figure 12B, P<0.05). Further, we tested 
whether TGF-β1 induces the TG2 promoter activity in OC cells. We transfected 
OC cells with a luciferase reporter gene downstream of the TG2 promoter, then 
treated the cells with TGF-β1, and collected the cell lysate to perform a luciferase 
assay. Compared with control, the results showed that TG2 promoter activity was 
enhanced by TGF-β1 (Figure 12C, P<0.05). All combined together, these data 
showed that TGF-β1 induces TG2 at transcriptional level. 
To test whether secreted TGF-β alters TG2 expression, we evaluated the 
effects of CM from OC cells on TG2 expression. Significant increase in TG2 
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mRNA level was induced by media conditioned by OC cells (3-fold, Figure 13), 
comparable to the effects of recombinant TGF-β1. To demonstrate that the 
effects are caused by TGF-β1, we utilized a TGF-β receptor kinase inhibitor 
(TKI). Pre-treatment with TKI led to partial decrease in TG2 induction (p =0.04), 
suggesting the effects of the CM in part are caused by secreted TGF-β1. 
However the incomplete effect of the inhibitor supports that OC cells secrete 
factors other than TGF-β1 that regulate TG2.  Such secreted factors may include 
LPA, VEGF or PDGF that are detectable in OC ascites (Xu et al 1995) 
(Yabushita et al 2003) (Matei et al 2006). Likewise, treatment of serum starved 
OC cells with the TGF-β receptor TKI diminished basal TG2 expression levels, 
suggesting that TGF-β1 is secreted by OC cells in an autocrine manner. 
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Figure 9: TGF-β1 induces TG2 upregulation in OC cells. A, Primary OC cell 
OVCA and OC cell lines SKOV3, C272/hTert/E7, Hey, and IGROV-1 were serum 
starved for 24 hours, then treated with 5ng/mL TGF-β1 for 24-48 hours. TG2 
expression was detected by Western blotting. GAPDH was tested as loading 
control. B, Western blotting for TG2 and GAPDH in normal ovarian surface 
epithelial cells (NOSE) N907 and N911, non-transformed mesothelial cell LP9 
treated with 5ng/mL TGF-β1 for 24-48 hours. 
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Figure 10: TG2 upregulation by TGF-β1 in OC cells at different conditions. 
A, To test the dose response to TGF-β1 in OC cells, C272hTert/E7 and SKOV3 
cells were treated with TGF-β1 (0.5ng/mL-15ng/mL) for 48 hours. TG2 
expression was detected by Western blotting. Densitometry quantifies the level of 
expression of TG2 relative to GAPDH. B, Western blotting for TG2 and GAPDH 
in SKOV3 cells plated on plastic (left panel) or on fibronectin (5ng/mL, right 
panel) coated plates. 
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Figure 11: TGF-β signaling pathway in OC cells. Expression of TGF-β 
receptors I and II, TGF-β intracellular mediators Smad2/3, Smad7, and TAK1 
were detected by Western blotting in OC cell lines C272, SKOV3, IGROV-1, and 
Hey, NOSE cells N907, N911, and N912, and mesothelail cell LP9. 
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Figure 12: TGF-β1 induces TG2 upregulation in OC cells at transcriptional 
level. A, C272/hTert/E7 cells were treated with 5ng/ml TGF-β1 for 3–24 hours, 
TG2 mRNA level was measured by qRT–PCR. B, C272/hTert/E7 cells were 
pretreated with 5μg/mL TGF-β neutralizing antibody for 1 hour before treatment 
with 5ng/ml TGF-β1. Total RNA were collected after 16 hour treatment with TGF-
β1. TG2 expression level was detected by qRT-PCR. C, C272/hTert/E7 cells 
treated with 5ng/ml TGF-β1 for 3–24hours. TG2 promoter activity was measured 
by luciferase reporter assay. *P<0.05. All these experiments were repeated in 
SKOV3 cells, and similar results were obtained. 
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Figure 13: TGF-β1 is secreted in OC cells in an autocrine manner. 
C272/hTert/E7 cells were serum straved for 24 hours, treated with 1μM TGF-β 
receptor I kinase inhibitor or vehicle for 1 hour, and then treated with 5ng/mL 
TGF-β1 and conditioned media of C272/hTert/E7 cells for 16 hours. Total RNA 
were extracted and TG2 mRNA expression level was detected by qRT-PCR. 
*P<0.05. 
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3.1.3 TGF-β1 induces TG2 enzymatic activity in OC cells 
As TG2 expression level is increased by TGF-β1, we investigated whether 
the enzymatic function of TG2 was also induced by TGF-β1.  OC cell line Hey, 
primary OC cell OVCA, NOSE and LP9 cells were treated with TGF-β1, and TG2 
enzymatic activity was measured by amine incorporation into total cellular 
proteins (Zhang et al 1998) (see materials and methods).  Increased TG2 activity 
was observed in OC cells (Hey and OVCA#16) (Figure 14A), but not in non-
transformed LP9 or NOSE# 1001 cells treated with TGF-β1 (Figure 14B). This 
increase in enzymatic function likely reflects TG2 expression induction by TGF-
β1 in OC cells, but not in non-transformed cells. However, we cannot exclude a 
direct effect of TGF-β1 on the enzymatic activity of TG2. 
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Figure 14: TGF-β1 induces TG2 enzymatic activity in OC cells. TGase assay 
were performed to detect TG2-catalyzed amine incorporation into proteins. Left 
panels: Napthol blue staining demonstrates equal loading of proteins per lane. 
Right panels: immunoblotting with HRP-conjugated streptavidin illustrates biotin-
conjugated amine incorporation into proteins, as described in Materials and 
methods. A, Hey cells and primary ovarian cancer cells (OVCA#16), B, 
mesothelial cells (LP9) and normal ovarian epithelial cell NOSE#1001 were 
treated with TGF-β1, and incubated with BPA to detect TG2 activity in the 
presence or absence of Ca++. Protein ladders formed when active TG2 catalyzes 
amine incorporation into proteins are framed in rectangles.  
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3.1.4. TGF-β1 induces TG2 in a Smad-dependent pathway 
To understand how TG2 expression is regulated by TGF-β in OC cells, 
activation of TGF-β-mediated signaling was assessed by measuring the 
phosphorylation of Smad2/3, the canonical signal transducers of TGF-β. The 
results showed that Smad2/3 were activated within 15 minutes and remained 
activated for up 24 hours after TGF-β1 treatment in SKOV3 cells (Figure 15A). 
Activation of TGF-β signaling was also measured in non-transformed NOSE and 
mesothelial cell LP9 (Figure 15B), and the results showed that Smad2/3 were 
only modestly activated by TGF-β1 in these cells.  
To investigate the effects of Smads on TG2 induction by TGF-β1, we 
utilized siRNA targeting Smad2/3 in OC cells. Knockdown of the Smad2/3 
complex prevented the induction of TG2 by TGF-β1 both at protein (Figure 16A) 
and mRNA level (Figure 16B). Even the basal level of TG2 expression was 
decreased when Smad2/3 were knocked down in OC cells, suggesting that 
engagement of Smad is important to the regulation of TG2 expression by TGF-β.  
Smads act as transcriptional regulators through direct binding to target 
gene promoter sequence (Zawel et al 1998) (Dennler et al 1998). To determine 
how Smads regulate TG2 expression in OC cells, a bioinformatic tool PROMO 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) 
was used to find out whether Smads directly regulate TG2 transcription. Several 
putative SBEs were identified in the -191 to -840 TG2 promoter region (Figure 
17A). Binding of Smad4 and pSmad3 to the TG2 promoter after TGF-β 
stimulation was demonstrated by ChIP utilizing primers encompassing the -269 
to -479 TG2 promoter fragment (Figure 17B & C), region where two SBEs were 
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predicted. These data suggest that TGF-β transcriptionally regulates TG2 
expression mainly through canonical Smad2/3 signaling pathway. 
Further, to consolidate the correlation between TG2 expression and Smad 
activation, we evaluated 30 human ovarian tumors on a tissue microarray by 
immunohistochemistry. H score was used to quantify the intensity and 
percentage of TG2 and pSmad3 staining in the tumor samples. Fisher's exact 
test was used to compare the relationship between TG2 and pSmad3 
expression. The results showed a significant positive correlation between TG2 
and pSmad3 staining in human ovarian cancer tissues (P=0.01, odds ratio=13.6, 
Figure 18 and Table 5), pointing to the clinical relevance of our findings. 
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Figure 15: Smad2 is activated by TGF-β1 in OC cells. A, SKOV3 cells were 
serum starved for 24 hours, and then treated with TGF-β1 for 15 minutes to 48 
hours. Smad2 activation was measured by Western blotting. B, NOSE cells 
(N907 and N911) and mesothelial cell LP9 were treated with TGF-β1 for 24 to 48 
hours. Smad2 activation was measured by Western blotting. 
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Figure 16: Knock down of Smad2/3 by siRNA blocked TG2 upregulation by 
TGF-β1. SKOV3 cells were transfected with Smad2/3 siRNA or control siRNA 
and treated with TGF-β1. TG2 expression level was detected by western blotting 
after 48 hour treatment (A) and qRT–PCR after 16 hour treatment (B). *P<0.05.  
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Figure 17: Smads bind to the TG2 promoter region.   
 79 
Figure 17: Smads bind to the TG2 promoter region. A. Schematic Smads 
binding sites on TG2 promoter sequence. B & C. Chromatin immunoprecipitation 
(ChIP) assay demonstrates the binding of pSmad3 and Smad4 to the TG2 
promoter. Cross-linked chromatin from C272/hTert/E7 cells treated with TGF-β1 
or vehicle was immunoprecipitated with pSmad3 antibody and amplified by 
regular PCR (left) and quantitative PCR (right) with TG2 promoter-specific 
primers. C. Cross-linked chromatin from C272/hTert/E7 cells treated with TGF-β1 
or vehicle was immunoprecipitated with Smad4 antibody and amplified by regular 
PCR with TG2 promoter-specific primers. For regular PCR, positive results are 
presented as PCR band about 210bp on agrose gel. For qPCR, results are 
presented as percentage of TG2 amplified from non-immunoprecipitated (input) 
chromatin. Chromatin immunoprecipitated with mouse immunoglobulin G (IgG) 
was amplified with primers for TG2 promoter as negative control. Chromatin 
immunoprecipitated with anti-RNA polymerase II was amplified with primers 
specific for human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
positive control. *P<0.05 
 
 80 
 
Figure 18: TG2 positively correlates with pSmad3 in human ovarian tumors. 
Representative immunohistochemistry (IHC) staining for TG2 and pSmad3 in 
human OC specimens are shown. Concordant positive staining in tumors #1 and 
#3 and concordant negative staining in tumor #2 are shown. Magnification (× 
100–400) is indicated. Experiments performed in collaboration with Mrs. 
Bhadrani Chelladurai. 
 
 
 
Table 5: Expression of TG2 and pSMAD3 in human ovarian tumors by 
histological type. 
 
 Serous Endometrioid Mucinous Total 
number 10 12 8 30 
TG2 positive 9 9 5 24 
pSmad3 
positive 
10 8 6 24 
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3.1.5. TAK1 is involved in TG2 upregulation by TGF-β1 
Except for canonical Smad signaling pathway, TAK1, another important 
TGF-β intracellular signaling mediator, was also investigated in the regulation of 
TG2 expression in OC cells. Similar to Smad2/3, TAK1 was activated within 15 
minutes and remained activated for up 24 hours after TGF-β1 treatment in OC 
cells (Figure 19). Different than Smad2/3, TAK1 activation was not detected in 
non-transformed NOSE and LP9 cells (data not shown), suggesting that TAK1 is 
only activated in cancer cells. 
Depending on the cellular context, after activation by TGF-β1, TAK1 may 
activate p38, the stress activated kinase JNK, or the NF-κB complex. Therefore, 
we measured the activation status of these TAK1 downstream signals. 
Phosphorylation of JNK was noted at late time-points (16-24 hours) after TGF-β1 
treatment, while phosphorylation of p38 went down in response to TGF-β1.  In 
contrast, the expression level of IKBα, the inhibitory unit for the  NF-kB complex 
was reduced within 1 hour after TGF-β1 treatment (Figure 19). This suggested 
that the NF-kB complex is a potential transducer of TGF-β-stimulated TAK1 
activity in OC cells.  
To find out if and which element in this pathway regulates TG2 
expression, next we utilized siRNA targeting the main elements of the cascade 
(TAK1, JNK2, p38 and p65, the trans-activating subunit of the NF-κB complex). 
Knockdown of TAK1 blocked the induction of TG2 by TGF-β1 at both protein and 
mRNA level (Figure 20), suggesting that TAK1 signaling pathway is also 
important for the regulation of TG2 by TGF-β1.  
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However, knockdown of p38 and JNK2 did not prevent TG2's induction by 
TGF-β1, at neither protein nor mRNA levels (Figure 21A & B), suggesting that 
these pathways are not involved in TG2 upregulation by TGF-β1. Further, siRNA 
targeting JNK2 or p38 caused a small increase in the basal level of TG2 
expression, suggesting these pathways exert an inhibitory effect on TG2 
expression. In contrast, knockdown of p65, the other TAK1 target downstream of 
TGF-β (Figure 22A), blocked TGF-β1-induced TG2, supporting that the NF-κB 
complex, activated downstream of TAK1, regulates TG2 (Figure 22B). In 
addition, overexpression of p65 potently induced TG2 mRNA expression level 
(Figure 22C), demonstrating the additional role of this pathway in TG2's 
transcriptional regulation in OC cells. In conclusion, TAK1, via NF-κB, 
participates in TG2 expression regulation by TGF-β1 in OC cells. 
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Figure 19: TAK1 and downstream signals in response to TGF-β1 in OC 
cells. SKOV3 cells were treated with TGF-β1 for 15 minutes to 48 hours. 
Phosphorylated and total TAK1, p38 and JNK, and IκBα were analyzed by 
Western blotting. 
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Figure 20: Knock down of TAK1 by siRNA blocked TG2 upregulation by 
TGF-β1. SKOV3 cells were transfected with TAK1 siRNA or control and treated 
with TGF-β1. TG2 expression level was detected by western blotting after 48 
hour treatment (A) and qRT–PCR after 16 hour treatment (B). *P<0.05.  
 
 85 
A. 
 
B. 
 
 
Figure 21: Effect of TAK1 downstream signals p38 and JNK on TG2 
upregulation by TGF-β1. A, SKOV3 cells were transfected with p38 siRNA or 
control and treated with TGF-β1. TG2 expression level was detected by western 
blotting after 48 hours treatment with TGF-β1 (left) and qRT–PCR after 16 hours 
treatment with TGF-β1 (right). B, SKOV3 cells were transfected with JNK2 siRNA 
or control and treated with TGF-β1, and TG2 expression level was detected by 
western blotting after 48 hours treatment with TGF-β1 (left) and qRT–PCR after 
16 hours treatment with TGF-β1 (right). 
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Figure 22: Effect of TAK1 downstream signal NF-κB on TG2 upregulation 
by TGF-β1. A, Western blotting for IκBα in SKOV3 cells treated with TGF-β1 
(left). Gene reporter assay for NF-κB promoter activity in OC cells treated with 
TGF-β1 (right). B, SKOV3 cells were transfected with p65 siRNA or control and 
treated with TGF-β1. TG2 expression level was detected by qRT–PCR. C, 
SKOV3 cells were transduced with p65 or control vector (pQCXIP) and TG2 
expression level was detected by qRT–PCR. *P<0.05. 
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3.2 TGF-β1 induced TG2 mediates Epithelial-Mesenchymal Transition and a 
cancer stem cell phenotype in OC cells  
 
3.2.1 TGF-β1 induces EMT in OC cells 
 TGF-β1 is a known inducer of EMT in other epithelial cell models (Xu et al 
2009), we therefore tested this function in OC cells. Our results showed that 
TGF-β1 treated SKOV3 cells underwent characteristic morphological changes of 
EMT, from a compact shape to an elongated, dispersed phenotype evident 24-72 
hours after treatment (Figure 23A).  The mesenchymal phenotype was confirmed 
by quantifying the expression of EMT markers, E-cadherin, N-cadherin, and of 
the transcriptional regulator Zeb1. A decrease in E-cadherin expression, 
associated with increased expression of N-cadherin, Zeb1, and TG2 were 
observed in TGF-β1 treated SKOV3 cells (Figure 23B). These data suggest that 
TGF-β1 can induce EMT in OC cells. 
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Figure 23: TGF-β1 induces EMT in OC cells. A, Morphological changes of 
SKOV3 cells treated with TGF-β1 for 24-72 hours (x100 magnification). B, 
SKOV3 cells were treated with TGF-β1 for 24-96 hours, epithelial marker E-
cadherin, mesenchymal marker Zeb1 and N-cadherin, and TG2 expression level 
were detected by Western blotting. 
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3.2.2 TG2 induces EMT in OC cells 
As TGF-β1 induces EMT in OC cells, and TG2 is upregulated by TGF-β1 
in OC cells, we sought to determine whether TG2 plays a role in EMT. Two 
ovarian cancer cell lines were used, one expressing endogenous TG2 (SKOV3) 
and one lacking TG2 expression (OV90). To better dissect the role of TG2 in 
EMT, SKOV3 cells were stably transfected with an antisense TG2 construct (AS-
TG2) or control vector (pcDNA3.1), and OV90 cells were stably transduced with 
full-length TG2 or control vector (pQCXIP). Decreased expression level of TG2 in 
AS-TG2 SKOV3 cells accompanied with increased expression level of epithelial 
marker E-cadherin was shown by Western blotting (Figure 24A, left). Control 
cells expressing endogenous TG2 displayed poorly organized adhesive junctions 
and loss of cell polarity and exhibited a fibroblast-like morphology. In contrast, 
cells stably transfected with AS-TG2 appeared compact, and cohesive (Figure 
24A, right). A similar difference in phenotype was noted in OV90 cells with or 
without TG2 overexpression. Increased expression level of TG2 in TG2-
transduced OV90 cells accompanied with decreased expression level of E-
cadherin was shown by Western blotting (Figure 24B, left). While control cells are 
compact and organized in tight structures, TG2-transduced OV90 cells are 
elongated and dispersed (Figure 24B, right). These observations suggest that 
increased TG2 expression was associated with a mesenchymal morphology and 
decreased E-cadherin expression level. 
Further, an immunofluorescent assay was done to test the expression of 
the epithelial marker, E-cadherin, and of the mesenchymal marker, vimentin, in  
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SKOV3 cells with and without TG2 expression. The results showed that SKOV3 
control cells dimly expressed E-cadherin and strongly stained with a vimentin 
antibody. In contrast, E-cadherin expression was increased and vimentin staining 
was diminished in AS-TG2 cells (Figure 25). These observations suggest that 
increased TG2 expression was associated with loss of epithelial phenotype and 
gain of mesenchymal phenotype.  
EMT renders cells more motile and invasive (Thiery 2002). We next 
examined whether the mesenchymal morphology observed in TG2-expressing 
cells is associated with increased invasiveness. For this, cells were plated in two-
dimensional and three-dimensional cultures in matrigel matrix. SKOV3 control 
cells formed conspicuous networks in matrigel, whereas AS-TG2 cells remained 
as solitary clumps (Figure 26A). Likewise, OV90 cells transduced with TG2 
invaded through the matrix as trabecullae, whereas OV90 control cells stayed in 
non-invading clumps (Figure 26B). These results show that TG2 promotes 
migration and invasion of ovarian cancer cells. 
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Figure 24: TG2 induces EMT in OC cells. A & B, Induction of EMT by TG2 
was assessed by EMT marker E-cadherin (left) and cell morphology (right, x100 
magnification) in SKOV3 transfected with pcDNA3.1 vector and AS-TG2 cells (A) 
and OV90 transduced with pQCXIP vector and TG2 cells (B). Experiments 
performed in collaboration with Dr. Minghai Shao. 
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Figure 25: TG2 expressing SKOV3 pcDNA3.1 cells exhibit a mesenchymal 
phenotype. Immunofluorescent staining for epithelial marker E-cadherin (Green) 
and mesenchymal marker vimentin (red) in pcDNA3.1 and AS-TG2–transfected 
SKOV3 cells. Nuclei are visualized by DAPI staining (Blue). 
 
A.                                                                   B. 
                 
 
Figure 26: TG2 enhances OC cells migration and invasion. Migration on two-
dimensional (2D) matrigel and invasion through three-dimensional (3D) matrigel 
were measured with SKOV3-pcDNA3.1 and AS-TG2 cells (A; ×100 
magnification) or OV90-pQCXIP and TG2 cells (B; ×100 magnification). 
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3.2.3 TG2 negatively regulates E-cadherin at transcription level by 
modulating the transcription repressor Zeb1 
Downregulation of E-cadherin expression is the central event in EMT 
(Zeisberg and Neilson 2009). We next investigated the mechanisms of E-
cadherin repression by TG2. As transcriptional repression of E-cadherin is a 
major process involved in loss of E-cadherin expression in many carcinomas 
(Berx and van Roy 2009), we first analyzed whether TG2’s effects on E-cadherin 
occur at the transcriptional level. For this, we measured E-cadherin mRNA in OC 
cells with and without TG2 expression. Reverse transcription-PCR (RT-PCR) 
showed that E-cadherin mRNA level was upregulated in AS-TG2 SKOV3 cells 
compared with control cells (Figure 27A, left). In contrast, E-cadherin mRNA level 
was downregulated in OV90 cells transduced with TG2 compared with vector-
transduced cells (Figure 27A, right). We then tested E-cadherin promoter activity 
in AS-TG2 and control SKOV3 cells transfected with an E-cadherin-luciferase 
reporter construct (DiFeo et al 2006). The gene reporter assay showed that E-
cadherin promoter activity was increased 2.6-fold by knocking down TG2 (Figure 
27B; P < 0.001). These data show that TG2 levels are negatively correlated with 
E-cadherin transcription expression.  
Several transcriptional repressors are reported as critical modulators of 
EMT, including Snail (Cano et al 2000), Slug (Bolos et al 2003), Zeb1 (Eger et al 
2005), Zeb2 (Comijn et al 2001), and Twist (Yang et al 2004). To find out 
whether TG2 regulates E-cadherin expression through one or more of these 
repressors, semiquantitative RT-PCR and real-time PCR were used to test the 
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expression of these transcription factors. Reduced mRNA expression levels for 
Slug, Zeb1, and Zeb2, but not for Twist1, Twist2, Snail1, and Snail 3, were 
observed in AS-TG2 compared with control cells (Figure 28A, left). Real-time 
PCR showed that Zeb1, Zeb2, and Slug mRNA expression levels were 
decreased by 80% in AS-TG2–transfected cells compared with controls, but the 
Snail1 expression level was not significantly different between the two cell types 
(Figure 28B, top). Similar trends were observed in OV90 +/- TG2 cells. Slug, 
Zeb1, and Zeb2 mRNA levels were increased in OV90-TG2 compared with 
control cells. In addition, Twist1 and Snail 3 mRNA levels were slightly 
upregulated in TG2-overexpressing cells (Figure 28A, right). Real-time PCR 
confirmed a 75% increase in mRNA expression level for Zeb1 and Zeb2 in 
OV90-TG2 compared with control cells, but no significant difference for Slug and 
Snail1 (Figure 28B, bottom). These data suggest that in ovarian cancer cells, 
TG2 expression correlates with expression of E-cadherin transcriptional 
repressors, particularly with that of Zeb1 and Zeb2.  
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Figure 27: TG2 negatively regulates E-cadherin at transcriptional level. A, 
semiquantitative RT-PCR for E-cadherin and GAPDH in SKOV3 control and AS-
TG2 cells (left) and in vector- and TG2-transduced OV90 cells (right). B, A gene 
reporter assay of E-cadherin promoter activity in AS-TG2 and pcDNA3.1 SKOV3 
cells, conducted as described in Materials and Methods. Experiments performed 
in collaboration with Dr. Minghai Shao. 
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Figure 28: TG2 modulates expression of E-cadherin transcription 
repressors Zeb1 and Zeb2. A. semiquantitative RT-PCR for E-cadherin 
transcriptional repressors in pcDNA3.1 and AS-TG2 SKOV3 cells (left) and 
pQCXIP- and TG2-transduced OV90 cells (right). Densitometry quantifies the 
level of expression of E-cadherin repressors relative to GAPDH. B, quantitative 
PCR for Zeb1, Zeb2, Slug, and Snail1 in SKOV3 cells transfected with AS-TG2 
or vector (top) and in OV90 cells transduced with TG2 or vector (bottom). 
*P<0.05. Experiments performed in collaboration with Dr. Minghai Shao. 
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Based on these results and on a recent report implicating Zeb1 in ovarian 
epithelial cell transformation (Hurt et al 2008), we focused on the effects of TG2 
on Zeb1. Consistent with RT-PCR data, lower Zeb1 expression at the protein 
level was observed in AS-TG2 compared with control cells (Figure 29A). To test 
whether Zeb1 negatively regulates E-cadherin in ovarian cancer cells, we used 
siRNA targeting Zeb1. E-cadherin expression level was upregulated in SKOV3 
cells transfected with Zeb1 siRNA compared with cells transfected with control 
siRNA (Figure 29B). These data suggest that TG2 is positively related with Zeb1 
expression, and Zeb1 negatively regulates E-cadherin expression. 
To investigate whether Zeb1 is needed for regulation of E-cadherin 
expression by TG2, we stably overexpressed Zeb1 in SKOV3 cells where TG2 
was knocked down. The expression level of E-cadherin, which was markedly 
increased by TG2 knockdown compared with control cells (Figure 30A, lane 2 
versus lane 1), was reduced significantly by overexpression of Zeb1 (Figure 30A, 
lane 3 versus lane 2). Consequently, overexpression of Zeb1 rescued the 
invasive phenotype in cells with decreased expression of TG2, as assessed by a 
two- or three-dimensional matrigel invasion assay (Figure 30B). These data 
suggest that Zeb1 plays a critical role in TG2-mediated regulation of E-cadherin 
expression and the invasive phenotype of ovarian cancer cells.  
Given the previously described role of TG2 in activating the NF-κB 
complex and Akt (Mann et al 2006, Verma et al 2008), and the known functions 
of these pathways in modulating EMT (Chua et al 2007, Grille et al 2003), we 
investigated whether the effects of TG2 on Zeb1 and EMT are induced as a 
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consequence of Akt or NF-κB activation. To test this, we overexpressed the p65 
subunit of NF-κB or a constitutively active form of Akt (CA-Akt) in ovarian cancer 
cells where TG2 was knocked down and compared the expression levels of Zeb1 
and E-cadherin to those in cells expressing endogenous TG2. Overexpression of 
p65 in AS-TG2 cells was confirmed by Western blotting for IκBα (Figure 31A) and 
overexpression of CA-Akt was verified by Western blotting for Akt (Figure 31B). 
Zeb1 expression level was lower in AS-TG2 cells compared with control cells, 
and this corresponded to increased E-cadherin expression level (Figure 31C, 
lane 2 versus lane 1). Overexpression of p65 in AS-TG2 cells rescued Zeb1 
expression level and repressed E-cadherin level (Figure 31C, lane 3 versus lane 
2).  
As assessed by a matrigel invasion assay, overexpression of p65 in AS-
TG2 cells led to an invasive phenotype comparable to that of control cells (Figure 
31D), suggesting that an important element in the process of TG2-induced EMT 
is the repressor Zeb1 induced by NF-κB. Overexpression of CA-Akt in AS-TG2 
cells also repressed E-cadherin level (Figure 31C, lane 4 versus lane 2) and 
induced an invasive phenotype (Figure 31D). However, CA-Akt overexpression 
did not affect Zeb1 (Figure 31C, lane 4 versus lane 2), suggesting that Zeb1 is 
not a downstream target of Akt. Collectively, these data indicate that TG2 
negatively regulates E-cadherin expression via inducing Zeb1 expression 
through activation of NF-κB, leading to EMT and increased cancer cell 
invasiveness. 
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Figure 29: TG2 regulates E-cadherin expression by modulating Zeb1. A. 
Western blotting for Zeb1 in pcDNA3.1- and AS-TG2–transfected SKOV3 cells. 
B. SKOV3 cells were transfected with siRNA targeting Zeb1 or with control 
siRNA (right), expression of Zeb1 and E-cadherin were detected by Western 
blotting. Densitometry quantifies Zeb1 expression relative to GAPDH. 
Experiments performed in collaboration with Dr. Minghai Shao. 
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Figure 30: Zeb1 is the mediator of TG2 induced EMT. A, SKOV3 pcDNA3.1 
and AS-TG2 cells were transduced with pQCXIP Zeb1 or control. Zeb1 and E-
cadherin expression was detected by Western blotting. B, Migration and Invasion 
of SKOV3-pcDNA3.1 and AS-TG2 cells transduced with pQCXIP or Zeb1 (×100 
magnification) were detected using Matrigel assay. Experiments performed in 
collaboration with Dr. Minghai Shao. 
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Figure 31: TG2 modulates Zeb1 expression by activation of p65. A. Western 
blotting for IκBα in AS-TG2 cells transduced with pQCXIP or p65. B. Western 
blotting for Akt in AS-TG2 cells transduced with pQCXIP or CA-Akt. C. Western 
blotting for Zeb1, E-cadherin, and GAPDH in SKOV3 pcDNA3.1 or AS-TG2 cells 
transduced with pQCXIP, p65, or CA-Akt. Densitometry quantifies the expression 
levels for Zeb1 and E-cadherin relative to GAPDH. D. Invasion through Matrigel 
of SKOV3-pcDNA3.1 and AS-TG2 cells transduced with pQCXIP, p65, or CA-Akt 
(×100 magnification). Experiments performed in collaboration with Dr. Minghai 
Shao. 
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3.2.4. N-terminal fibronectin binding domain of TG2 induces EMT in OC 
cells 
TG2 is a multifunctional protein with several functional domains. To 
understand how TG2 participates in EMT induction, we used an OC cell model 
that does not express endogenously TG2 (OV90 cells) and stably transduced 
these cells by pQCXIP with wild-type TG2, a TG2 N-terminal fragment that 
contains the region binding FN (tTG1-140), a TG2 enzymatic mutant (C277S) 
and a TG2 GTPase mutant (R580A) (Figure 32). First we measured the 
expression of EMT markers in these engineered cells by Western blotting and 
qRT-PCR. Quantification of EMT markers at protein and mRNA levels 
demonstrated that both wild-type TG2 and tTG1-140 but not the TG2 enzymatic 
mutant C277S or TG2 GTPase mutant R580A induce downregulation of E-
cadherin and upregulation of Zeb1 at both protein level (Figure 33A) and mRNA 
level (Figure 33B, P<0.05). Next, we measured the motility and invasiveness of 
these engineered cells. The results showed that both wild-type TG2 and tTG1-
140 but not C277S or R580A induced cell invasion through matrigel consistent 
with a mesenchymal phenotype (Figure 33C). These data suggest that the FN-
binding domain of TG2, lacking both enzymatic and GTPase function is sufficient 
to induce EMT. Interestingly, it has been recently shown that this fragment is 
essential for TG2's secretion into the ECM and interaction with the matrix (Chou 
et al 2011). Indeed, we measured cell adhesion to FN and observed that 
expression of both full length TG2 and tTG1-140 increases cell adhesion to FN, 
as previously reported (Akimov and Belkin 2001) (Hang et al 2005) (Figure 34, 
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P<0.05). These data suggest that TG2’s role facilitating cell interaction with the 
ECM is implicated in EMT. 
 
A.  
 
B. 
C. 
 
D. 
 
 
 
Figure 32: Schematics of TG2 constructs transduced into OV90 cells. A. 
wild-type TG2, B. a TG2 N-terminal fragment that contains the FN binding 
domain (tTG1-140), C. a TG2 enzymatic mutant (C277S) and D. a TG2 GTPase 
mutant (R580A). 
 
 
aa    1                            140      C277 335  358               460            R580 583                       687           
NH2 COOH 
aa    1                            140      C277 335  358               460            R580 583                        687           
NH2 COOH X 
aa    1                            140      C277 335  358               460            R580 583                        687           
NH2 COOH X 
1                           140 
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Figure 33: Wild-type TG2 and N-terminal fibronectin binding domain of TG2 
induce EMT in OV90 cells.  
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Figure 33: Wild-type TG2 and N-terminal fibronectin binding domain of TG2 
induce EMT in OV90 cells. A, TG2, E-cadherin and Zeb1 expression levels 
were measured by western blotting in OV90-pQCXIP, wild-type (wt)-TG2,  tTG1-
140, TG2 enzymatic mutant C277S and TG2 GTPase mutant R580A transduced 
cells. B, E-cadherin and Zeb1 mRNA expression levels were measured by 
quantitative reverse transcriptase (qRT)–PCR in OV90-pQCXIP, wt-TG2, tTG1-
140, C277S, and R580A transduced cells. *P<0.05. C, Invasion through matrigel 
using two-dimensional (2D) and three-dimensional (3D) cultures of OV90-
pQCXIP, wt-TG2, tTG1-140, C277S, and R580A transduced cells (×100 
magnification). 
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Figure 34: Wild-type TG2 and N-terminal fibronectin binding domain of TG2 
promote OV90 cells adhere to FN. Adhesion to FN was measured by solid 
phase assay using OV90-pQCXIP, wt-TG2, tTG1-140, C277S, and R580A 
transduced cells. *P<0.05. 
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3.2.5. TGF-β1 induces an ovarian cancer stem cell phenotype 
An important step in the process of OC dissemination is the formation of 
cellular spheroids. These allow cancer cells to float in the abdominal cavity as 
multi-cellular aggregates, protecting them from environmental stresses and 
facilitating invasion into the mesothelium (Allen et al 1987, Sodek et al 2009). 
Spheroid formation is also recognized as a cancer stem cell feature (Dontu et al 
2003). As TGF-β1 can induce EMT, and EMT is associated with cancer stem cell 
phenotype (Mani et al 2008), we investigated whether TGF-β1 enhanced OC 
spheroid formation by inducing TG2.  Increased size and number of spheroids 
were induced by TGF-β1 in IGROV1 (Figure 35, P<0.05, left) and SKOV3 cells 
(not shown).  TGF-β1 a ls o incre a s e d the  s ize  of s phe roids  forme d by IGROV1 
cells and by cells disaggregated from human ovarian tumors (Figure 35, right).  
Prior studies indicated that cancer cells with stem cell phenotype 
aggregate as spheroids when cultured under low adherence conditions in the 
absence of differentiating factors (Al-Hajj et al 2004, Zhang et al 2008).  Further, 
cancer cells cultured as spheroids are enriched in cells with stem phenotype 
(Dontu et al 2003).  We therefore quantified the percentage of cells harboring the 
OCIC phenotype within spheroids and tested the effects of TGF-β1 on this cell 
population.  We used CD44 and CD117 as the cell surface markers, based on 
the demonstration that cells double staining for these markers display the 
functional characteristics of stem cells, including the ability to differentiate, to 
generate tumors in mice and to be chemoresistant (Zhang et al 2008).  We 
observed that as compared to monolayer cultures, IGROV1 spheroids were 
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enriched in CD117+ (35% vs. 3%) and CD44+/CD117+ (2.5% vs. 1%) cell 
population (Figure 36A). TGF-β1 tre a tme nt of IGROV1 ce lls  e nriche d the  
CD44+ (36% vs. 23%) and CD44+/CD117+ cell subpopulations (2.5% vs. 1.4%, 
Figure 36B). These data show that TGF-β1 induces spheroid formation in OC 
cells and increases the CD44+/CD117+ population. 
 
 
Figure 35: TGF-β1 induces spheroid formation of OC cells. Spheroid 
formation induced by TGF-β1 in IGROV-1 cells. Columns correspond to mean 
number of spheroids ± SEM (left). *P<0.05. Morphology of spheroids formed by 
IGROV-1 cells and primary OC cells treated with TGF-β1 (right, x100 
magnification). 
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A. 
IGROV-1 monolayer IGROV-1 spheroids
 
B. 
IGROV-1 control IGROV-1 TGF-β1
 
Figure 36: TGF-β1 induces an ovarian cancer stem cell phenotype. A. Flow 
cytometry quantifies CD44+/CD117+ population in IGROV-1 cells cultured as 
monolayer or spheroids. B. Flow cytometry quantifies CD44+/CD117+ population 
in IGROV-1 cells treated with and without TGF-β1 for 24 hours. 
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3.2.6. TG2 is upregulated in ovarian cancer stem cells  
In summary, we have shown that TGF-β1 induces EMT and a stem cell 
phenotype in OC cells, which are crucial for OC metastasis.  We also 
demonstrated that TGF-β1 upregulates TG2, which induces EMT in OC cells 
(data shown above) and promotes OC metastasis (Satpathy et al 2007).  Next 
we investigated the relationship between TG2 expression level and OC stem 
cells. For this, we measured TG2 expression in OC spheroids and in 
CD44+/CD117+ OC cells.  We found that cells growing as spheroids expressed 
higher TG2 levels and displayed mesenchymal characteristics (increased 
vimentin, decreased E-cadherin expression) compared to cells cultured as mono-
layer (Figure 37A, left panel- primary OC cells, right panel- IGROV-1 cells).   
To investigate relevance to human OC, we isolated CD44+/CD117+ cells 
from human tumors and measured TG2 mRNA expression levels in double 
staining cells, un-fragmented tumor, ascites, and double negative cells. Our 
results showed that TG2 expression level was increased in CD44+/CD117+ cells 
compared to whole tumor or cells isolated from ascites (Figure 37B, P<0.05) or to 
CD44-/CD117- cells dissociated and sorted from ovarian tumors (n=3, Figure 
37C, P<0.05). These data suggest that TG2 expression level is increased in OC 
cells grown as spheroids and in the CD44+/CD117+ cell population. 
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A. 
 
B.                                                               C. 
 
Figure 37: TG2 is upregulated in ovarian cancer stem cells. A, Western 
blotting for TG2, E-cadherin and vimentin in IGROV-1 (right) and primary OC 
cells (left) cultured as monolayer or spheroids. B, TG2 mRNA expression levels 
were measured by qRT-PCR in CD44+/CD117+cells from human ovarian tumor 
and compared with bulk tumor and cells isolated from ascites. C, Average TG2 
expression levels measured by qRT-PCR in CD44+/CD117+ cells isolated from 
human ovarian tumors compared with CD44-/CD117- (n=3). *P<0.05. 
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3.2.7. TG2 induces an ovarian cancer stem cell phenotype 
To test whether TG2 plays a role in spheroid formation, TG2 was knocked 
down by transducing in primary cancer cells dissociated from tumors (n=3) with 
shRNA targeting TG2 followed by sorting based on expression of stem cells 
markers (CD44+/CD117+), and by stable transfection of AS-TG2 in SKOV3 cells. 
We then measured spheroid formation by OC cells under stem cell condition.  
Our results showed that spheroid formation was blocked when TG2 is knocked 
down in both SKOV3 cells and human OC stem cells (Figure 38).  
We next investigated whether TG2 alters the abundance of OCIC cell 
population by quantifying the percentage of CD44+/CD117+ cells in SKOV3 cells 
+/- TG2. Significantly fewer CD44+/CD117+ cells were identified in SKOV3-AS-
TG2 (0.7%) compared to control cells (7.8%; Figure 39), suggesting that TG2 is 
important to this phenotype.  
To further support the link between TG2 and cancer stem cells, the 
expression levels of stem cell specific transcription factors Nanog, Oct3/4, and 
Sox-2, were measured in cells +/- TG2.  Increased levels of Nanog and Sox-2 
were noted in SKOV3-control and OV90-TG2 cells compared to SKOV3-ASTG2 
and OV90-vector, respectively (Figure 40A). Oct 3/4 expression level was 
increased in OV90-TG2 compared to control cells, but was not different in 
SKOV3 +/-TG2. Likewise, the Western blot results showed that STAT3, a 
transcription factor which is important for the maintenance of stem cell self-
renewal and pluripotency, was activated in TG2 expressing SKOV3 pcDNA3.1 
and OV90 tTG cells (Figure 40B). Furthermore, Western blot and IF results 
showed that β-catenin, the main effector of Wnt signaling pathway is induced in 
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TG2 expressing SKOV3 pcDNA3.1 cells compared with SKOV3 AS-TG2 cells 
(Figure 41). These data suggest that TG2 may promote OC stem cell phenotype 
by increasing the expression of stem cell specific transcription factors. 
Collectively these data support the concept that TG2 expression level correlates 
with an ovarian cancer stem cell phenotype. 
A. 
 
B. 
 
Figure 38: TG2 promotes spheroid formation of OC cells. Morphology of 
spheroids formed by CD44+/CD117+ cells from human OC transduced with short 
hairpin RNA (shRNA) targeting TG2 or control (A, × 100) or by SKOV3 AS-TG2 
and pcDNA3.1 cells (B, × 400). 
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Figure 39: TG2 enriches CD44+CD117+ population. Flow cytometry quantifies 
CD44+/CD117+ cells in SKOV3 cells transfected with AS-TG2 or vector. 
Representative (A) and averages of four replicates (B) are shown. *P<0.05. 
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Figure 40: Stem cell specific transcription factors are upregulated in TG2 
expressing cells. A. Quantitative PCR measured expression levels for Nanog, 
Oct3/4 and Sox 2 in SKOV3 AS-TG2 or control cells (left) and in OV90-TG2 or 
control cells (right). *P<0.05. B. TG2, phosphorylated STAT3, and total STAT3 
were measured by Western blot in SKOV3 AS-TG2 or control cells (left) and in 
OV90 TG2 or control cells (right). 
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Figure 41: β-catenin is upregulated in TG2 expressing SKOV3 pcDNA3.1 
cells compared with SKOV3 AS-TG2 cells. A. TG2 and β-catenin were 
detected by Western blot in SKOV3 pcDNA3.1 and AS-TG2 cells. B. β-catenin 
was detected by Western blot in nuclear extracts of SKOV3 pcDNA3.1 and AS-
TG2 cells. C. β-catenin was detected by IF in SKOV3 pcDNA3.1 and AS-TG2 
cells. 
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3.2.8. TG2 is required for TGF-β1 induced EMT, cancer stem cell phenotype 
and OC metastasis 
To test the significance of TG2 to TGF-β1 induced EMT, stem cell 
phenotype and metastasis, we utilized SKOV3 cells stably transfected with an 
antisense construct (AS-TG2) or the empty vector pcDNA3.1. Induction of EMT 
by TGF-β1, as assessed by cell morphology (Figure 42A) or quantification of 
EMT markers (Figure 42B), was prevented in SKOV3-ASTG2 compared with 
control cells. This suggests that TG2 is an important downstream mediator for 
TGF-β induced EMT.  
Next, we investigated whether TG2 is relevant to TGF-β1 induced OC 
stem cell phenotype. SKOV3 pcDNA3.1 and AS-TG2 cells were treated with 
TGF-β1, and CD44+/CD117+ OC stem cell population were measured by flow 
cytometry. Our results showed that TGF-β1 induced three-fold increase in the 
number of CD44+/CD117+ in SKOV3 pCDNA3.1 cells, but not in SKOV3 AS-
TG2 cells (Figure 43). These data suggest that TG2 is needed for TGF-β1 
induced cancer stem cell phenotype. 
Then we used the TGF-β receptor I serine threonine kinase inhibitor, 
SD208 (Mohammad et al 2011) to block the TGF-β signaling pathway in SKOV3 
pcDNA3.1 and AS-TG2 cells. TG2 induction and EMT markers were detected by 
Western blotting. Our results showed that SD208 blocked TGF-β-induced Smad 
2/3 activation and TG2 induction in both SKOV3-ASTG2 and control cells (Figure 
44). This confirms that TG2 is upregulated by TGF-β through Smad signaling 
pathway, and that this upregulation can be blocked by the TGF-β receptor 
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inhibitor. Treatment with SD208 also increased E-cadherin expression in SKOV3-
ASTG2 cells, to a greater degree than in control cells. This suggests that the 
TGF-β receptor inhibitor can block TGF-β induced EMT in OC cells, and cells 
without TG2 expression are more sensitive to the TGF-β inhibitor treatment, 
further supporting the concept that TG2 is important in TGF-β induced EMT. 
Next, we tested the effect of this inhibitor in vivo, in an intraperitoneal (i.p.) 
xenograft model in nude mice. We observed a significant difference between the 
number of peritoneal implants derived from control vs. AS-TG2 cells (142 vs. 
383, P=0.006, Figure 45A), consistent with our previous observations (Satpathy 
et al 2007) and supporting TG2’s role in regulating OC peritoneal dissemination. 
We also found that SD-208 blocked almost completely the formation of peritoneal 
metastases derived from SKOV3 AS-TG2 cells (16 vs. 142, P=0.006, Figure 
45A), as compared with metastases derived from SKOV3 pCDNA3.1 cells (278 
vs. 383, P=0.08, Figure 45A). These data suggest that SD208 not only inhibits 
EMT in vitro, but also blocks tumor metastasis in vivo. These data are also 
consistent with the in vitro finding that TG2 knockdown cells are more sensitive to 
the inhibitory effect of SD208, which confirms that TG2 is required for OC 
metastasis. To further confirm that TG2 is a TGF-β downstream effector required 
for OC metastasis, TG2 expression level was detected by Western blotting in 
tumor samples from SD208 treated and untreated SKOV3 pCDNA3.1 and AS-
TG2 i.p. mice. Our results showed that TG2 expression level in AS-TG2 derived 
tumors treated with SD-208 was almost undetectable, whereas TG2 expression 
level was only modestly decreased in control tumors from animals treated with 
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SD208 (Figure 45B). Collectively, these data suggest that TG2 is required for 
TGF-β induced EMT, cancer stem cell phenotype in vitro and tumor metastasis in 
vivo. 
 
A. 
 
B. 
 
 
Figure 42: TG2 is required for TGF-β1 induced EMT in OC cells. A. Cellular 
morphological change in SKOV3 pcDNA3.1 and AS-TG2 cells after TGF-β1 
treatment (x100 magnification). B. EMT markers E-cadherin and N-cadherin were 
detected by Western blot in SKOV3 pcDNA3.1 and AS-TG2 cells after TGF-β1 
treatment. 
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Figure 43: TG2 is required for TGF-β1 induced ovarian cancer stem cell 
phenotype. Flow cytometry quantifies CD44+/CD117+ population in SKOV3 AS-
TG2 and pcDNA3.1 cells treated with TGF-β1 for 24 hours. 
 
 
 
Figure 44: TGF-β receptor I kinase inhibitor, SD208, blocked TG2 
upregulation and EMT in OC cells. SKOV3 AS-TG2 and control cells were pre-
incubated with SD208 (0.5 μg/ml) or vehicle for 1h before treatment with TGF-β1 
(5 ng/ml). Activation of Smad3 and total Smad3 were detected by western 
blotting after treatment with TGF-β1 for 30 minutes. E-cadherin and TG2 
expression level were detected by western blotting after treatment with TGF-β1 
for 48 hours. 
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Figure 45: TGF-β receptor I kinase inhibitor, SD208, blocked OC metastasis 
in vivo. A. Left, average number of peritoneal implants ± SD in mice injected with 
SKOV3 pcDNA3.1 or AS-TG2 cells and treated with SD208 or control (n=4 per 
group). *P<0.05. Right, representative pictures of peritoneal implants on 
mesentery adjacent to the bowel in the four experimental groups. B. Western 
blotting measured TG2 expression level in xenograft tumors from the four 
experimental groups. 
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3.3 TG2 induces chemoresistance in OC cells 
3.3.1 TG2 mediates response to cisplatin in OC cells  
One important property of cancer stem cells is chemoresistance. Cisplatin, 
a DNA cross-linking agent, is the first line chemotherapy for OC (Armstrong et al 
2006). Given TG2’s role in maintenance of stem cell homeostasis in OC cells, we 
next investigated whether TG2 plays a role in response to cisplatin. For this, 
SKOV3 cells stably transfected with AS-TG2 and control vector (pcDNA3.1) were 
treated with varying concentrations of cisplatin for 24 h. To avoid potential clonal 
bias, the effects of cisplatin were measured in two different clones expressing 
low TG2 levels (clone G and M, Figure 46A). Knockdown of TG2 sensitized cells 
to cisplatin, with a 2-fold decrease in the inhibitory concentration (IC50), from 5 
μM in control cells to 2.5 μM in AS-TG2 cells (Figure 46B). Results were 
confirmed by BrdU assay (data not shown).  
To mimic the interaction with the extracellular matrix, cells were plated on 
fibronectin and treated with cisplatin. Similar results were obtained, the IC50 
being decreased from >5 μM in controls to 2.5 μM in AS-TG2 cells and data were 
verified by BrdU assay (Figure 46C). This was accompanied by a corresponding 
increase in apoptotic or necrotic cells, as counted by Trypan blue exclusion, with 
>10-fold increase in the number of dead cells after exposure to cisplatin in AS-
TG2 cells versus controls (Figure 46D).  
We next assessed the effects of cisplatin on the clonogenic potential of 
SKOV3 cells transfected with vector or with AS-TG2. Clonogenic assay, also 
called colony formation assay, is an in vitro assay to test cell survival based on 
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the ability of a single cell to grow into a colony. It is used to determine the effects 
of cytotoxic agents on tumor cell proliferation (Franken et al 2006). Our results 
showed that colony formation by cells with low TG2 expression was suppressed 
more significantly by low concentrations of cisplatin (1 and 2 μM) compared with 
control cells (Figure 47). Along with the results of the proliferation assays, these 
observations suggest that OC cells in which TG2 was knocked down are more 
sensitive to cisplatin treatment. 
Next, we tested whether stable overexpression of TG2 in OC cells 
decreased sensitivity to cisplatin. For this, an ovarian cancer cell line with low 
endogenous expression of TG2 (OV90) was transfected with human full-length 
TG2. A stably transfected clone was identified by immunoblotting after selection 
with G418 (Figure 48A). OV90 cells with and without TG2 expression were 
treated with various concentrations of cisplatin, and MTT assay was performed to 
detect the effect of cisplatin on these cells.  Our results showed that stable 
expression of TG2 increased resistance to cisplatin compared with cells 
transfected with empty vector (pcDNA3.1), with a 2-fold increase in IC50 from 5 
μM in control cells to 10 μM in cells overexpressing TG2 (Figure 48B). These 
data suggest that TG2 induces ovarian cancer cells to become resistant to 
cisplatin treatment. Together with the effects of TG2 knockdown, these results 
indicate that TG2 is implicated in ovarian cancer cells’ response to cisplatin. 
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A.                                                 B. 
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Figure 46: TG2 knockdown in SKOV3 OC cells enhances sensitivity to 
cisplatin.  
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Figure 46: TG2 knockdown in SKOV3 OC cells enhances sensitivity to 
cisplatin. A. TG2 was knocked down using stable transfection with an antisense 
(AS-TG2) construct cloned into pcDNA3.1. Western blot demonstrates TG2 
levels in SKOV3 cells stably transfected with pcDNA3.1 vector (control) and with 
AS-TG2 (clones #G and #M). B. Effects of cisplatin on cell proliferation were 
assessed by MTT assay. SKOV3 cells transfected with pcDNA3.1 (control) and 
two AS-TG2 stable clones (#G and #M) were treated with different 
concentrations of cisplatin for 48 h. C. Effects of cisplatin on cell proliferation in 
SKOV3 cells transfected with pcDNA3.1 (control) and AS-TG2 cells being plated 
on the matrix protein, fibronectin (FN). D. Number of floating cells after 48 h 
treatment with cisplatin in AS-TG2 versus control cells. *P< 0.05. 
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Figure 47: Knock down of TG2 in SKOV3 cells induces response to 
cisplatin. Clonogenic assay assessed colony formation after 48 h exposure to 
cisplatin in SKOV3 cells transfected with AS-TG2 or pcDNA3.1. Data represent 
averages of triplicate experiments ± SEM. *P< 0.05. 
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Figure 48: Overexpression of TG2 in OC cells induces resistance to 
cisplatin. A. Wild-type (WT) TG2 was transfected in OV90 ovarian cells. Stable 
transfection were selected based on resistance to G418. Western blot shows 
levels of TG2 in several clones (clone #17 is positive) and in vector-transfected 
cells (controls). B. OV90 cells transfected with pcDNA3.1 (control) and WT-TG2 
were treated with different concentrations of cisplatin for 48 hours, and the 
effects of cisplatin were measured by MTT assay. Data represent averages of 
triplicate experiments ± SEM. *P< 0.05. 
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3.3.2 TG2 protects against apoptosis induced by cisplatin in EOC cells 
Cisplatin induces apoptosis in EOC cells by activating the mitochondrial 
machinery (Henkels and Turchi 1997). Having noticed a remarkable increased 
number of detached cells in SKOV3 AS-TG2 cells exposed to cisplatin compared 
with controls (Figure 44D), we measured apoptosis induced by cisplatin. 
Apoptosis was first determined by measuring the activity of caspase-3 in OC 
cells after cisplatin treatment in SKOV3 pcDNA3.1 and AS-TG2 cells versus 
untreated cells as controls. We observed increased activation of caspase-3 in 
SKOV3 AS-TG2 cells treated with cisplatin compared with untreated control and 
with cisplatin-treated SKOV3 pcDNA3.1 cells (Figure 49A).  
Next, we measured apoptosis in SKOV3 pcDNA3.1 and AS-TG2 cells via 
TdT-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay. Our 
results showed that the percentage of apoptotic cells after exposure to cisplatin 
was 5-fold higher in cells stably transfected with AS-TG2 compared with control. 
Cisplatin increased the percentage of TdT-positive cells from 1% in controls to 
9% in AS-TG2 cells (Figure 49B). These results suggest that apoptosis induced 
by cisplatin is enhanced in cells with decreased TG2 expression. We also 
measured cleavage of pro-caspase-9, degradation of the X-linked inhibitor of 
apoptosis protein (XIAP) and cytoplasmic release of cytochrome c after cisplatin 
treatment and found them to be more pronounced in AS-TG2 cells compared 
with controls after cisplatin treatment (Figure 49C), suggesting that TG2 exerts 
an anti-apoptotic role in EOC cells exposed to cisplatin.  
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Figure 49: TG2 protects OC cells against cisplatin-induced apoptosis.  
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Figure 49: TG2 protects OC cells against cisplatin-induced apoptosis. A. 
Activation of caspase-3 was measured by a fluorometric assay. SKOV3 cells 
stably transfected with pcDNA3.1 and AS-TG2 were treated with 10 μM cisplatin 
for 24 h. Data represent averages of two independent experiments performed in 
duplicate ± SEM. (B) Percentage of apoptotic cells after treatment with cisplatin 
was assessed by TdT-mediated deoxyuridine triphosphate nick-end labeling 
(TUNEL) assay. SKOV3 cells stably transfected with AS-TG2 or vector were 
treated with 10 μM cisplatin for 24 h. Percentage of TUNEL-positive cells was 
quantified by counting of 10 microscopic fields (x200) per specimen. Data 
represent average of duplicate experiments ± SEM. All counts were obtained in 
duplicate. The number of TdT-positive cells in wells not treated with cisplatin was 
close to zero. C. Cisplatininduced apoptosis was measured by western blotting 
using antibodies for pro-caspase-9, cytochrome c and XIAP. β-Actin was used as 
a control. SKOV3 cells stably transfected with pcDNA3.1 and AS-TG2 were 
treated with cisplatin (10 μM) for 24 and 48 h. *P< 0.05. Experiments performed 
in collaboration with Dr. Daniela Petrusca.  
 
 131 
3.3.3 TG2 protects EOC cells from cisplatin-induced apoptosis through 
activation of NF-κB signaling pathway 
To understand the mechanism by which TG2 exerts its anti-apoptotic role 
OC cells, we examined the effects of Akt and NF-κB, two survival pathways 
commonly involved in development of drug resistance in EOC. For this, we 
overexpressed a constitutively active form of Akt (CA-Akt) and the p65 subunit of 
NF-κB in SKOV3 AS-TG2 and pcDNA3.1 cells and examined cisplatin-induced 
apoptosis in these cells. There was no statistically significant difference between 
cisplatin-induced caspase-3 activity in SKOV3 pcDNA3.1 cells transduced with 
empty vector and cells transduced with p65 (Figure 50A). Similarly, Akt 
overexpression failed to inhibit cisplatin-induced apoptosis in these SKOV3 
pcDNA3.1 cells. In contrast, cisplatin-induced caspase-3 activation was rescued 
by overexpressing constitutively active p65, but not by CA-Akt in AS-TG2 cells 
(Figure 50A), suggesting that the anti-apoptotic effect of TG2 was exerted mainly 
through activation of NF-κB. 
Knowing that cisplatin-induced apoptosis proceeds primarily through 
activation of the mitochondrial pathway, we examined the effects of cisplatin on 
the mediators of this intrinsic apoptotic pathway. We found that cisplatin-induced 
activation of caspase-9 in AS-TG2 cells was significantly inhibited by 
overexpression of p65, but to a lesser extent by CA-Akt compared with vector-
transfected cells (Figure 50B). These data support NF-κB as the major mediator 
in TG2 induced anti-apoptotic effect. 
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Next we investigated by western blot the level of expression of other 
markers of apoptosis induced by cisplatin (pro-caspase-9, cytochrome c and 
XIAP) in SKOV3 AS-TG2 and pcDNA3.1 cells transduced with vector, p65 or CA-
Akt. Overexpression of constitutively active p65 subunit prevented cleavage of 
pro-caspase-9 and XIAP in AS-TG2 cells treated with cisplatin (Figure 50C, left 
panel). Partial cleavage of XIAP after exposure to cisplatin was still detected in 
AS-TG2 cells transduced with p65, however, to lesser degree than in AS-TG2 
cells transduced with empty vector. Cisplatin-induced cytochrome c release was 
also decreased by overexpression of p65 in AS-TG2 cells. These findings 
support the previous observations that p65 rescues AS-TG2 ovarian cancer cells 
from cisplatin-induced apoptosis. In contrast, CA-Akt did not affect cisplatin-
induced cleavage of pro-caspase-9 or XIAP and release of cytochrome c in AS-
TG2 cells, suggesting that Akt does not play a major role in TG2-mediated 
ovarian cancer cells' resistance to cisplatin. Interestingly, in control cells, 
expressing intact levels of TG2, cleavage of pro-caspase-9 or XIAP was not 
observed after 48h exposure to cisplatin, showing a cisplatin-resistant 
phenotype. Overexpression of CA-Akt or p65 did not significantly alter basal or 
cisplatin-induced pro-caspase-9 or XIAP levels in control cells. Collectively, these 
data suggest that TG2 induces cisplatin resistance via NF-κB signaling pathway. 
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Figure 50: Reconstitution of NF-κB, but not of Akt, restores resistance to 
cisplatin in AS-TG2 cells. 
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Figure 50: Reconstitution of NF-κB, but not of Akt, restores resistance to 
cisplatin in AS-TG2 cells. SKOV3 cells transfected with AS-TG2 or pcDNA3.1 
were transduced with constitutively active p65, CA-Akt or vector (pQCXIP) and 
treated with cisplatin. A. Caspase-3 activity was measured by fluorometric assay 
at 24 h after cisplatin treatment. The results are expressed as inhibitory potency 
(mean % inhibition ± SEM; n=2) of constitutively active p65 or CA-Akt compared 
with empty vector on the caspase-3 activity induced by cisplatin treatment. Note 
the potent inhibitory effect of p65 overexpression on the cisplatin-induced 
caspase-3 activity in cells transfected with AS-TG2. All other treatments failed to 
significantly inhibit (or further activate) cisplatin-induced caspase-3 in either 
control vector- or ASTG2-expressing cells. B. Apoptosis was assessed by 
western blotting of cytochrome c, pro-caspase-9 and XIAP after 48 hours of 
cisplatin treatment. β-Actin was used as a control. C. Caspase-9 activation was 
measured using a fluorometric assay in pcDNA3.1 or AS-TG2 cells transduced 
with constitutively active p65, CA-Akt and vector control (pQCXIP) and treated 
with cisplatin for 24 h. Data are expressed as mean fold increase versus control 
caspase-9 activity (measured as fluorescent units per minute per milligram 
protein) ± SEM (n = 3). Note that only p65-overexpressing AS-TG2 cells failed to 
activate caspase-9 in response to cisplatin treatment. *P< 0.05. Experiments 
performed in collaboration with Dr. Daniela Petrusca. 
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3.3.4 TG2 regulates NF-κB activity in EOC cells 
Having noticed that p65 rescued cisplatin-induced apoptosis in EOC cells 
to greater extent than CA-Akt, we next examined the function of the Akt and NF-
κB pathways in EOC cells in the presence or absence of functional TG2. For this, 
we compared levels of phosphorylated Akt in SKOV3 cells stably transfected with 
AS-TG2 or pcDNA3.1 in basal conditions. We found decreased activation of Akt 
in AS-TG2 cells compared with controls as measured by decreased 
phosphorylation at Ser473. This occurred in parallel to decreased phosphorylation 
of the focal adhesion kinase (FAK) in AS-TG2 cells compared with control cells 
(Figure 51A).  
To see if this phenomenon depends on TG2 enzymatic activity or not, we 
used a chemical inhibitor of TG2 KCC009 to test its effect on Akt, FAK and NF-
κB activity.  Interestingly, inhibition of TG2 enzymatic activity by the TG2 inhibitor 
KCC009 did not affect activation of Akt, suggesting that the effects of TG2 on this 
survival pathway may be independent of its enzymatic function (Figure 51B). 
However, FAK phosphorylation was modestly reduced after treatment with 
KCC009, suggesting that TG2 enzymatic activity may be needed for focal 
adhesion. 
Next, we measured the effects of TG2 expression and enzymatic function 
on NF-κB activity. Using a reporter assay, we found that the activity of the NF-κB 
complex was decreased 2-fold in cells stably transfected with AS-TG2 compared 
with controls (Figure 51C). Likewise, inhibition of TG2 enzymatic function by 
KCC009 led to decreased NF-κB activity in SKOV3 cells (Figure 51F). This 
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inhibition of the NF-κB promoter activity was paralleled by a corresponding 
increase in expression levels of inhibitory IκBα level in cells transfected with AS-
TG2 versus controls (Figure 51D). The expression level of IκBα was also 
increased by treatment with the TG2 enzyme inhibitor KCC009 (Figure 51E). 
This suggested that the expression and the enzymatic function of TG2 are 
essential in regulating the expression level of the inhibitory unit IκBα and 
subsequently the activity of the NF-κB complex.  
To investigate whether these observations have therapeutic relevance, we 
measured the effects of TG2 inhibitor KCC009 on OC cell proliferation. The TG2 
inhibitor KCC009 had anti-proliferative effects in SKOV3 cells, with an IC50 of 
<250 μM (Figure 51G). This effect may be partly explained by the inhibition of the 
NF-κB survival pathway, but other contributory mechanisms cannot be excluded. 
These results suggested that inhibition of TG2 may serve as a novel modality to 
enhance sensitivity of ovarian cancer cells to cisplatin. We therefore tested 
whether the combination of KCC009 and cisplatin exerts synergistic effects in 
SKOV3 cell proliferation. Measurement of growth inhibition indices after 
treatment with each agent and with the two-drug combination led to a calculated 
combination index (CI) of 0.89 (Figure 51H), using the median-effect principle of 
Chou et al (Chou and Talalay 1984). This CI value indicates a modest synergistic 
effect between cisplatin and the TG2 inhibitor.  
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Figure 51: TG2 modulates Akt and NF-κB activity in OC cells and TG2 
inhibitors sensitize OC cells to cisplatin.  
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Figure 51: TG2 modulates Akt and NF-κB activity in OC cells and TG2 
inhibitors sensitize OC cells to cisplatin. A. Western blot for Ser473Akt, 
phosphorylated FAK and GAPDH in SKOV3 cells stably transfected with AS-TG2 
and vector. B. Western blot for Ser473Akt, phosphorylated FAK and GAPDH in 
SKOV3 cells treated with KCC009 for 24 h at a concentration of 250 and 500 μM. 
C. NF-κB promoter activity measured by a reporter assay in SKOV3 cells stably 
transfected with AS-TG2 and vector. D. Western blot for IκBα in SKOV3 cells 
stably transfected with AS-TG2 and vector. E. Western blot for IκBα in SKOV3 
cells treated with KCC009 for 24 h at a concentration of 250 and 500 μM. F. NF-
κB promoter activity measured by a reporter assay in SKOV3 cells treated with 
the TG2 inhibitor KCC009 at a concentration of 250 and 500 μM. G. Effects of 
KCC009 on ovarian cancer cell proliferation were measured by MTT assay. Data 
represent average of triplicate experiments ± SEM. H. KCC009 has synergistic 
effects when combined with cisplatin (CI=0.89) in SKOV3 cells. Cell proliferation 
was measured by MTT assay after 48 h treatment with cisplatin, KCC009 and the 
combination of two drugs and the CI was measured based on the median-effect 
principle of Chou et al. The median-effect plot was analyzed using Calcusyn. 
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CHAPTER 4: DISCUSSION 
4.1 Summary of results   
In this study we showed that TGF-β1 secreted in the OC milieu regulates the 
expression and function of TG2 in OC cells but not in normal ovarian surface epithelial 
cells. This regulation proceeds primarily through the canonical Smad signaling 
pathway, which can be blocked by a TGF-β neutralizing antibody, a TGF-β receptor 
kinase inhibitor, or siRNA targeting the Smad family of transcription factors. 
Additionally, non-Smad signaling (TAK1 and NF-κB) is also involved in TG2 
upregulation by TGF-β1. TGF-β induced TG2 promotes EMT by negatively regulating 
E-cadherin expression. More specifically, TG2 induces E-cadherin transcription 
suppressor Zeb1 by activating NF-κB signaling pathway. This leads to increased cell 
invasiveness in vitro and tumor metastasis in vivo. The N-terminal FN-binding domain 
of TG2 (tTG 1-140), lacking both enzymatic and GTPase function, induced EMT in OC 
cells. Increased TG2 expression also correlates with increased spheroid formation, 
enriched OCICs population, and enhanced expression of the stem cell-specific 
transcription factors Nanog, Oct3/4, Sox-2, and STAT3. A TGF-β receptor kinase 
inhibitor SD-208 blocked OC peritoneal metastasis in a manner consistent with 
suppression of TG2 expression levels. Further, we showed that TG2 protects ovarian 
cancer cells from cisplatin-induced apoptosis by regulating NF-κB activity. Therefore, 
we propose a model whereby TGF-β-induced TG2 modulates EMT, metastasis, OCIC 
homeostasis and chemoresistance (Figure 52). These findings contribute to a better 
understanding of the mechanisms of OC metastasis modulated by TG2 and point to 
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potential therapeutic interventions targeting TG2 or TGF-β signaling to interrupt OC 
tumor progression. 
 
Figure 52: Proposed mechanisms by which TGF-β-induced TG2 regulates 
EMT, spheroid formation, metastasis and chemoresistance. 1. TGF-β1 activates 
Smad-dependent signaling pathway to upregulate TG2 expression in OC cells. 2. 
TGF-β1 activates TGF-β-activated kinase 1 (TAK1), which activates downstream 
NF-κB to upregulate TG2 expression in OC cells. The other two TAK1 downstream 
signaling, p38 and JNK, might be involved in inhibition of TG2 upregulation by TGF-
β1 in OC cells. 3. By modulating E-cadherin transcription repressor Zeb1, 
overexpressed TG2 in OC cells induces EMT to promote tumor metastasis. 4. 
Overexpressed TG2 in OC cells induces spheroid formation and a stem cell 
phenotype. 5. Overexpressed TG2 protects OC cells from cisplatin-induced 
apoptosis by regulating NF-κB activity. 
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4.2 TGF-β1 induces TG2 overexpression in OC cells 
First, we demonstrated that TGF-β1 is secreted in the OC milieu in an 
autocrine manner. TGF-β1 is secreted at higher concentrations by OC cells 
compared to non-transformed NOSE cells (Figure 8A), and similarly, higher TGF-
β1 levels were detected in OC associated ascites compared to non-malignant 
effusions (Figure 8B). These data are in agreement with other studies showing 
that TGF-β1 is secreted in malignant OC ascites (Abendstein et al 2000) (Santin 
et al 2001). While we found that TGF-β1 secretion in OC associated ascites at an 
average level around 1719 pg/mL, Abenstein et al reported an average TGF-β1 
secretion level around 5443 pg/mL in 10 OC ascites samples (Abendstein et al 
2000), and Santin et al reported an average secreted TGF-β1 level around 407 
pg/mL in 28 OC asitic fluid samples (Santin et al 2001). These differences may 
be due to different techniques of measurement and different methods of 
collection and storage for the specimens analyzed. Further, by stimulating OC 
cells with conditioned media, we found that TG2 expression level was increased, 
and that this increase could be blocked by a TGF-β receptor kinase inhibitor 
(Figure 13). These data suggested that TGF-β1 is secreted by OC cells in an 
autocrine manner. 
Second, activation of TGF-β signaling in OC cells induced the expression 
and activity of TG2, an enzyme overexpressed in OC and linked to OC 
metastasis (Satpathy et al 2007). The specificity of TGF-β's effect was 
demonstrated as TG2 induction was blocked by a neutralizing antibody or a TGF-
β receptor kinase inhibitor. Interestingly, we observed that TGF-β1 did not induce 
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TG2 expression or enzymatic activity in non-transformed NOSE and LP9 cells. 
Like OC cells, these cells express type I and II TGF-β1 receptors and the other 
elements of the signaling cascade, as previously reported (Yamada et al 1999) 
(Dunfield et al 2002). Our results showed that TG2 is not induced by TGF-β1 in 
NOSE cells, which coincided with attenuated Smad and TAK1 activation. We 
speculate that the lesser extent of activation of Smad2/3 in NOSE cells may be 
due to increased expression levels of the inhibitory Smad7 in these cells, as we 
show in Figure 11.  
Third, we point to the canonical Smad signaling pathway as the principal 
mechanism of TG2 expression regulation by TGF-β1 in OC cells.  By using 
siRNA targeting Smad2/3, we found that knock down of Smad2/3 not only 
blocked TG2 upregulation by TGF-β1, but it also decreased the basal expression 
level of TG2.  The ChIP assay further confirmed that TG2 expression is 
transcriptionally regulated through Smad signaling pathway by demonstrating 
direct binding of pSmad3 to the TG2 promoter. This binding was enhanced in 
response to TGF-β stimulation. Previously a TGF-β1/BMP4 response element 
had been identified in the mouse TG2 gene promoter. This element was 
considered responsible for the stimulatory effect of TGF-β1 and the inhibitory 
effect of BMP4 on transglutaminase in a mink lung cell line Mv1Lu cells (Ritter 
and Davies 1998). However, others have shown that the effect of TGF-β1 on 
TG2 expression is cell-specific. For example, TGF-β1 stimulates TG2 expression 
in Mv1Lu cells, but inhibits TG2 expression in the mouse preosteoblastic cell line 
MC3T3 E1 (Ritter and Davies 1998). It has been reported that TGF-β1 can 
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induce TG2 enzymatic activity in normal and transformed human epidermal 
keratinocytes, and that this enhanced activity is related to increased TG2 
expression levels, which is consistent with our findings. However, the authors 
claimed that TGF-β1 regulates TG2 expression through a mechanism dependent 
on protein synthesis (George et al 1990). In human subconjunctival fibroblasts, it 
was reported that TGF-β2, but not TGF-β1, induces TG2 expression and activity 
through PI3K-Akt signaling pathway (Jung et al 2007). Likewise, it was TGF-β2, 
but not TGF-β1, that has been shown to induce TG2 activity in human lens 
epithelial cell line HLE-B3 (Shin et al 2008). Therefore, our data are the first to 
show that TGF-β1 transcriptionally regulates TG2 in human ovarian cancer cells 
via Smads binding elements within the promoter of the gene. Moreover, the 
positive correlation we found between TG2 expression and Smad activation in 
human ovarian tumors suggested that the mechanism is operative in vivo (Figure 
18).  
On the other hand, the non-canonical TAK1 pathway was also engaged in 
the regulation of TG2 in OC cells. By using specific silencing or overexpression 
of TAK1 targets, we demonstrated that the main TG2 transcriptional regulator in 
the non-canonical pathway is the NF-κB complex. This is consistent with 
previous report that the tumor necrosis factor (TNF)-α transcriptionally modulates 
TG2 expression via a NF-κB motif in the promoter of the gene in liver cells (Yee 
et al 1997).  TGF-β can activate NF-κB through Smad-dependent signaling 
pathway in keratinocytes (Lopez-Rovira et al 2000). It also can activate NF-κB 
through a Smad-independent TAK1 signaling pathway in osteoclasts (Gingery et 
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al 2008). In our study, we demonstrated cooperation between Smads and the 
NF-κB complex in the process of TG2 transcription regulation by TGF-β1 in 
ovarian cancer cells. By crosslinking NF-κB inhibitory protein IκB and promoting 
its degradation, TG2 is known to induce NF-κB activity (Mann et al 2006).  Thus, 
a feed forward loop may exist between TG2 and NF-κB.   
TG2 is required for activation of the large latent complex (LLC) in bovine 
endothelial cells (Kojima et al 1993). LTBP, the latent TGF-β binding protein, 
which is essential for correct folding and efficient secretion of TGF-β1, is cross-
linked to the ECM by TG2 and thus targets the LLC to the matrix, where TGF-β1 
can be activated (Nunes et al 1997). In addition, NF-κB is an important mediator 
that induces TGF-β expression and activity in monocytes (Rameshwar et al 2000) 
and fibrosarcoma cells (Perez et al 1994). Therefore, the feed forward loop 
between TG2 and NF-κB may be expanded to a large network between TGF-β1, 
NF-κB and TG2. Indeed, the relationship between TG2, NF-κB and TGF-β1 was 
further confirmed in Swiss 3T3 cells, in which TG2 induced the expression and 
bioactivity of TGF-β1, a process mediated by NF-κB (Telci et al 2009). 
 
4.3 TG2 induces EMT in OC cells by modulating E-cadherin transcriptional 
repressor Zeb1 
First, by using knockdown and overexpression of TG2 in OC cells, we 
demonstrated that TG2 expression level in OC cells is correlated with an 
elongated mesenchymal morphology accompanied by the loss of epithelial 
marker E-cadherin and gain of the mesenchymal markers N-cadherin and 
vimentin. This phenotypical change led to increased migration and invasion of 
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OC cells in matrigel. Our study showed for the first time that TG2 promotes EMT 
in cancer cells (Shao et al 2009). Our findings were later confirmed in a breast 
cancer model (Kumar et al 2010) and in an epidermoid carcinoma model (Lin et 
al 2011), suggesting that the phenomenon observed is more general, and not OC 
restricted. As EMT is required for initiation of tumor metastasis, this novel 
function of TG2 sheds new light on the mechanism by which overexpressed TG2 
enhances metastasis of ovarian cancer (Satpathy et al 2007), breast cancer 
(Mehta et al 2004) (Mangala et al 2007), pancreatic ductal adenocarcinoma 
(Verma et al 2006), and melanoma (Fok et al 2006). 
Second, by exploring the transcriptional suppressors of E-cadherin, we 
found that TG2 expression is correlated with the expression of zinc finger 
transcription factor Zeb1. By knockdown and overexpression of Zeb1 in OC cells 
with and without TG2 expression, we identified Zeb1 as an important mediator of 
TG2-induced EMT. Further, we demonstrated that TG2 activates NF-κB to 
induce Zeb1 upregulation. Thus, for the first time, we reported that TG2 induced 
EMT by modulating E-cadherin transcriptional suppressor Zeb1, a process which 
is mediated by NF-κB. This mechanism was later reproduced in breast cancer 
(Kumar et al 2010) and epidermoid carcinoma (Lin et al 2011).  
Zeb1 represses E-cadherin transcriptional expression by binding to the E-
box element on E-cadherin promoter (Eger et al 2005). It can also repress 
expression of genes that regulate cell polarity, such as Crumbs3, HUGL2 and 
Pals1-associated tight junction protein (Aigner et al 2007). Therefore, Zeb1 is an 
important player in regulating epithelial cell polarity and tumor progression. 
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Several signaling pathways have been reported to regulate Zeb1 expression to 
induce EMT in various cancer cells, such as TGF-β1 in breast cancer 
(Shirakihara et al 2007), NF-κB in breast cancer (Chua et al 2007), IGF-1 in 
prostate cancer (Graham et al 2008), and estrogen in ovarian cancer (Hurt et al 
2008). Members of microRNA (miR)-200 family have been reported to be 
suppressors of Zeb1 and Zeb2 to inhibit EMT (Korpal et al 2008) (Park et al 
2008). In our study, we demonstrated that NF-κB regulates Zeb1 expression to 
promote EMT in OC cells. Given the network between TG2, NF-κB and TGF-β1, 
and the fact that Zeb1 is a downstream target of TGF-β1, we can not exclude a 
direct effect of TGF-β1 on Zeb1 in OC cells. In addition to Zeb1, we also 
observed increased Zeb2 and Slug expression in OC cells overexpressing TG2. 
This suggested that Zeb2 and Slug may also be involves in TG2 induced EMT, 
but the exact mechanism needs to be further studied.  
Third, by introducing wild-type TG2, N-terminal FN-binding domain (tTG1-
140), TG2 enzymatic mutant (C277S) and TG2 GTPase mutant (R580A) into the 
TG2-null OC cell line OV90, we found that tTG1-140 is sufficient to induce EMT. 
This was demonstrated by decreased E-cadherin, increased Zeb1, and 
increased migration and invasion in matrigel compared with control cells. As this 
fragment is important in cell adhesion to FN, these data suggest that the TG2-
mediated interaction between the tumor cells and the ECM may be involved in 
the process of EMT induction.  
Cell surface TG2 acts as a co-receptor for β1 and β3 integrin to bind FN, 
and thus TG2, FN, and β1 or β3 integrin form a tertiary adhesion complex to 
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promote cell adhesion and migration (Akimov et al 2000).  Except for being a co-
receptor, TG2 also modulates β1 integrin expression level by inhibiting β1 
integrin degradation through calpain-induced proteolysis (Satpathy et al 2007). 
Integrins are a superfamily of transmembrane glycoproteins that mediate cell 
adhesion to the ECM. About 18 α and 8 β subunits have been described and 
these subunits can form up to 24 heterodimers, each with a distinct function. β1 
integrin has been reported to be an important mediator for TGF-β-induced EMT 
(Bhowmick et al 2001). TGF-β directly upregulates β1 integrin expression and 
evidence for binding of Smad3/4 to the promoter of β1 integrin has been provided 
(Yeh et al 2010). In addition, αV integrins, such as αV β1 and αV β3 can interact 
with the arginine-glycine-aspartic acid (RGD) sequence of LAP. This protein 
associates with TGF-β, induce its conformational change, leading to its activation 
(Ludbrook et al 2003). My work and these previous studies suggest that TGF-β 
signaling, TG2, and integrins are interconnected at multiple levels. 
As transmembrane receptors on the cell surface, integrins connect the 
ECM with the intracellular cytoskeleton. Upon binding to the ECM, integrins 
cluster to form focal adhesion complexes. This process initiates outside-in 
signaling. On the other hand, intracellular signaling can change the conformation 
of integrins and induce inside-out signaling. These signaling pathways include 
focal adhesion kinase (FAK), integrin-linked kinase (ILK), Src, Rac, Rho, and 
cdc42 small GTPases. Engagement of integrins can also activate cell surface 
receptor tyrosine kinases such as PDGFR, EGFR, VEGFR, and FGFR even in 
the absence of ligand binding, and this integrin-receptor interaction further 
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activates downstream PI3K/Akt and Ras/Raf/MAPK signaling pathways (Yamada 
and Even-Ram 2002).  
Integrin signaling is important for OC progression. For instance, ILK has 
been reported to be overexpressed in OC (Lossner et al 2009) and to promote 
OC metastasis (Ahmed et al 2003). Moreover, ILK is involved in TGF-β induced 
migration and invasion of OC cells (Lin et al 2007). Recently, Zeb1 was reported 
to be a downstream mediator of ILK to promote EMT in bladder cancer (Matsui et 
al 2012). Taken together, we speculate that via engagement of integrins and 
perhaps by activating downstream ILK signaling, tTG1-140 upregulates Zeb1 
expression and induces EMT. Future work investigating how tTG1-140 activates 
ILK needs to be performed to confirm this proposed hypothesis. 
However, both the TG2 enzymatic mutant (C277S) and the GTPase 
mutant (R580A) contain a functional FN-binding domain couldn’t induce EMT in 
OV90 cells. As TG2 has no secretory signals, it is delivered to cell surface by 
interacting with β1 integrin in perinuclear recycling endosomes (Zemskov et al 
2011). We also know that the tTG1-140 fragment is secreted, as it is detectable 
in the conditioned media of stably transduced OV90 cells. We speculate that the 
two other mutants may not be transferred to cell surface successfully after 
protein synthesis, and perhaps are not able to engage the integrins on the cell 
surface and fail to initiate integrin downstream signaling. Interestingly, mutation 
of Arg-579 in rat TG2 (Arg-580 in human TG2) to Ala induces a conformational 
change of TG2 (Begg et al 2006a). This GTP-independent mutant adopts a semi-
compact conformation, which is different from the compact form of GTP-bound 
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wild-typeTG2. Likewise, Cys-277 also involves in allosteric regulation of TG2 by 
forming a stabilizing H-bond between Cys-277 and Tyr-516. Substitution of Cys-
277 with Ala or Ser disrupts the stability of compact TG2 (Begg et al 2006a). The 
conformational change of C277S and R580A may block the transfer of TG2 to 
the plasma membrane. This proposed explanation remains to be proved by using 
IF tracking to follow cellular localization of the mutant proteins.  
 
4.4. TG2 induces an ovarian cancer stem cell phenotype 
The concept of cancer stem cells was first defined in leukemia (Bonnet 
and Dick 1997) and later on was applied to solid tumors. Ovarian cancer stem 
cells were first identified using the cell surface markers CD44 and CD117 (Zhang 
et al 2008).  One important property of stem cells is self-renewal, as evidenced 
by the ability to form spheroids in vitro (Dontu et al 2003). We demonstrated here 
that TG2 expression level was increased in ovarian cancer stem cells, both in OC 
cells grown as spheroids and in the CD44+/CD117+ population isolated from 
human ovarian tumors. Knock-down of TG2 decreased the percentage of 
CD44+/CD117+ cells in cancer cell lines and spheroid formation by OC cells. 
These data suggested that TG2 is required for the maintenance of the OC stem 
cell phenotype.  As we showed previously that TG2 induces EMT in OC cells,  
our findings are in agreement with the previous report that EMT generates the 
breast cancer stem cell phenotype (Mani et al 2008). Indeed, we also observed 
increased vimentin and decreased E-cadherin expression in cells grown as 
spheroids. In ovarian cancer, it is possible that only cells undergoing EMT and 
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acquiring migratory abilities can be shed from the primary tumor site, can self-
renew, survive in the peritoneal cavity (via spheroid formation) and can form 
metastatic tumors in distant organs.  
The process of self-renewal is important for stem cells to maintain 
pluripotency and represents one of the key characteristics of “stemness”. A set of 
transcription factors including Nanog, Oct3/4, Sox-2, and STAT3 play critical 
roles in the maintenance of stem cells’ self-renewal (Niwa 2007). Oct3/4 and 
Sox-2, together with c-Myc and klf4, known as Yamanaka factors, can induce 
pluripotency in both mouse and human somatic cells (Takahashi and Yamanaka 
2006) (Takahashi et al 2007). Oct3/4 and Sox-2, together with Nanog and Lin28, 
were also reported to induce pluripotent stem cells from human somatic cells (Yu 
et al 2007). These studies indicate that Oct3/4 and Sox-2 are essential to 
maintain stem cell pluripotency and “stemness”.  We showed here that the 
expression level of these stem cell specific transcription factors Nanog, Oct3/4, 
Sox-2, and STAT3 are upregulated in TG2 expressing ovarian cancer cells. 
These data suggest that TG2 might induce a stem cell phenotype in ovarian 
cancer cells by modulating stem cell specific transcriptional factors.  
Except for these transcriptional factors, several signaling pathways, such 
as TGF-β, Wnt, Notch, and hedgehog (Hh), are also critical regulators of stem 
cell self-renewal, pluripotency, and differentiation (Liu et al 2007) (Takebe et al 
2011). We showed that β-catenin, the downstream effector of canonical Wnt 
signaling pathway, is upregulated in TG2 expressing ovarian cancer cells. We 
also demonstrated that TGF-β induces spheroid formation and increases the 
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CD44+/CD117+ population in OC cells, and these effects are blocked in cells 
where TG2 is knocked down. These data further support that TG2 plays an 
important role in the maintenance of ovarian cancer stem cell homeostasis. 
After ovarian cancer stem cells were first isolated using the cell surface 
markers CD44 and CD117, other markers have been described to identify 
ovarian cancer cells with stem cell features, e.g. CD133, ALDH1, and others (see 
Introduction: section 1.5). Ovarian cancer cells bearing those markers possess 
some of the same stem cell characteristics: self-renewal, ability to initiate tumors, 
and chemoresistance. At present, there is no accepted consensus on a defined 
marker or a combination of several markers as the common standard marker for 
ovarian cancer stem cells, as the field is evolving. All these markers need to be 
tested by further studies.  One limitation of our study is that we limited the CSC 
markers studied to CD44/CD117 based on our best interpretation of the available 
literature. In future work, to better understand the mechanism by which TG2 
modulates ovarian cancer stem cell homeostasis, some of other marker, such as 
CD133 or ALDH1 might be used alone or in combination with CD4/CD117 to 
isolate ovarian cancer stem cells 
. 
4.5. TG2 induces chemoresistance in OC cells 
 By knocking down and overexpressing TG2 in OC cells, we demonstrated 
that TG2 expression levels in OC cells correlates with OC cells’ survival after 
cisplatin treatment, suggesting that TG2 mediates resistance of these cells to 
cisplatin. This finding is consistent with TG2’s role in maintenance of ovarian 
 152 
cancer stem cells described above, as cancer stem cells are known for 
chemoresistance. There are several mechanisms that might mediate 
chemoresistance of cancer stem cells. First, CSCs can exist in a long-term 
quiescent or dormant state (Li and Bhatia 2011). The resting state renders CSCs 
resistant to agents that block DNA synthesis in highly proliferating cells, such as 
cancer cells. Second, CSCs express high levels of adenosine triphosphate 
(ATP)-binding cassette (ABC) transporters that regulate the efflux of 
chemotherapy agents from cells (Moitra et al 2011). This ability has been 
exploited to isolate ovarian CSCs as they can effectively exclude the Hoechst 
33342 dye, and these CSCs have been named the “side population” (Szotek et al 
2006). There are 8 subfamilies of ABC transporters: ABCA to ABCG, arsenite 
and antimonite transporter (ANSA) (Mahadevan and List 2004). It has been 
demonstrated that CD44+/CD117+ ovarian CSCs exhibit upregulated ABCG2 
(Zhang et al 2008). Third, CSCs express regulators of drug metabolism such as 
aldehyde dehydrogenase isoform 1 (ALDH1), which induces chemoresistance in 
hematopoietic cells (Magni et al 1996). Increased expression of ALDH1 has been 
detected in several types of CSCs such as breast (Ginestier et al 2007) and 
ovary stem cells (Silva et al 2011). Fourth, CSCs demonstrate enhanced 
expression/activation of growth factors and anti-apoptotic signaling pathways 
(Gangemi et al 2009). In ovarian cancer, both protein kinase B (Akt)- and nuclear 
factor-kappa B (NF-κB)-regulated survival pathways are reported to be implicated 
in acquired cisplatin resistance (Yang et al 2006) (Mabuchi et al 2004). Here we 
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showed that TG2 induces chemoresistance by regulating NF-κB activity in OC 
cells. 
 TG2 has been implicated in doxorubicin resistance in breast cancer cells 
(Kim et al 2006) and its role in this process was linked to adhesion-mediated 
activation of intracellular signaling (Herman et al 2006). We also found that TG2 
knockdown led to decreased levels of Akt phosphorylation in SKOV3 cells, in 
parallel with decreased levels of FAK activation. However, reconstitution of Akt 
activity through overexpression of CA-Akt in AS-TG2 cells altered only partially 
cisplatin-induced activation of caspases-9 and -3, suggesting that Akt was not 
the primary pathway through which TG2 protects cancer cells from 
chemotherapy-induced apoptosis. While activation of Akt by TG2 in SKOV3 cells 
may be related to facilitation of integrin engagement with subsequent FAK 
phosphorylation, our findings do not exclude other non-adhesion-mediated 
mechanisms leading to Akt activation. It is interesting that TG2 inhibition by 
KCC009 had discrepant effects on the levels of phosphorylated FAK compared 
with the levels of phosphorylated Akt in SKOV3 cells, suggesting that perhaps 
Akt activation in these cells may be modulated through other pathways. Indeed, a 
recent report suggests that the phosphatase and tensin homolog (PTEN) is a 
direct TG2 substrate in pancreatic cancer cells (Verma et al 2008). It is possible 
that such a mechanism is operative in ovarian cancer cells as well.  
 In contrast to the inability of CA-Akt to fully reduce cisplatin-mediated 
apoptosis in the absence of TG2, overexpression of constitutively active p65 
subunit of NF-κB alone significantly reduced apoptosis induced by platinum in 
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AS-TG2 cells. This finding implicates activation of the NF-κB survival pathway by 
TG2 as the main escape mechanism from cisplatin-induced apoptosis. Given that 
in certain cellular contexts Akt plays a role in activating NF-κB (Gustin et al 
2006), the discrete roles played by the two pathways may not be fully separated. 
We further examined the activity of the NF-κB complex in ovarian cancer cells 
and found that NF-κB activity is modulated by the level and function of TG2. This 
is consistent with prior studies in pancreatic cancer cells, where TG2 has been 
implicated in constitutive activation of the NF-κB complex, presumably through 
destabilization of IκBα. The inhibitory IκBα subunit appears to be a direct 
substrate for cross-linking mediated by TG2 in malignant pancreatic cells (Mann 
et al 2006). Abnormally cross-linked IκBα would then be targeted for proteosomal 
degradation and displaced from the NF-κB complex, leading to its activation. We 
found increased levels of IκBα levels in SKOV3 cells where TG2 has been 
knocked down, suggesting that a similar mechanism of TG2-mediated NF-κB 
activation is functional in EOC cells.  
Furthermore, we demonstrate for the first time that KCC009, a 
dihydroisoxazole inhibitor of TG2 (Choi et al 2005), inhibits directly NF-κB and 
increases levels of IκBα in SKOV3 cells. KCC009 was investigated as a potential 
anticancer agent in glioblastoma, its effects being attributed to disruption of the 
extracellular matrix (Yuan et al 2005) and to inhibition of the Akt survival pathway 
and its targets (Yuan et al 2007). Interestingly, KCC009 did not significantly affect 
activation of Akt in ovarian cancer cells, contrasting the findings in glioblastoma. 
This may be due to the fact that Akt is constitutively active in SKOV3 cells 
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(Altomare et al 2004) (Arboleda et al 2003) and in ovarian tumors (Cheng et al 
1992) and thus may be less dependent on outside-in signaling compared with 
glioblastoma cells. Constitutive activation of Akt in ovarian cancer cells has been 
attributed to low levels of expression of the phosphatase PTEN (Arboleda et al 
2003) or to Akt gene amplification. Our data suggest that the cytotoxic effects of 
KCC009 in SK0V3 ovarian cancer cells and its modest synergistic activity in 
combination with cisplatin may be due to its inhibitory effect on the NF-κB 
survival pathway.  
 
4.6. Concluding remarks and future studies 
 In summary, in these studies we investigated the mechanisms of TG2 
upregulation in OC and the pathways by which TG2 induces OC metastasis and 
chemoresistance. We demonstrated that TGF-β1, a cytokine involved in tumor 
progression, is secreted in the OC milieu in an autocrine manner, and that TGF-
β1 induces TG2 expression and enzymatic function in OC cells. Aside from TGF-
β1, there are many other pathways that regulate EMT, tumor metastasis, cell 
survival, and chemoresistance. These pathways include, but are not limited to 
Wnt, Notch, Hedgehog, PDGF, EGF, and VEGF. Some of these growth factors 
or ligands are expressed or secreted in the OC milieu through autocrine or 
paracrine mechanisms. Future work will explore whether TG2 may be inducible 
by other pathways in the OC tumor milieu and dissect the mechanisms involved. 
We also showed that TGF-β1-induced TG2 promotes EMT in OC cells and 
plays an important role in the homeostasis of OCICs, which are critical for OC 
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peritoneal metastasis and chemoresistance. These findings indicate that TG2 is 
a critical player implicated in ovarian cancer progression and suggest that the 
protein may be a target for future drug development, particularly focusing on 
agents that block OC progression. To proceed to this next step, it will be 
important to understand which part and function of the molecule is critical to the 
induction of EMT. My work suggests that the FN-binding domain of TG2 is 
implicated in EMT in ovarian cancer. If these findings are confirmed, then the 
focus can be placed on discovering small molecules that inhibit the interaction 
between TG2 and FN. As this site of protein-protein interaction has been 
biochemically mapped to a well-defined β5-β6 domain that inserts tightly into a 
pocket of FN, it may be possible to design inhibitors blocking this site of 
interaction. This could be performed by designing an assay that quantitatively 
measures the binding between TG2 and FN that can be adapted to high 
throughput screening of large libraries of compounds. It would be anticipated that 
by blocking TG2-FN binding, these small molecules will inhibit cell binding to the 
matrix. By inhibiting cellular adhesion, such agents could have a direct effect on 
peritoneal metastasis, as a critical step in this process is represented by cell 
adhesion to the ECM. In addition, my data suggest that inhibitors of TG2-FN 
interaction could also block EMT, and therefore they would have effects on 
OCICs and metastasis.  
To determine the role of TG2 in OC progression, different OC cell lines 
were engineered to either overexpress or to express low levels of TG2. This 
approach changed the expression level of TG2 expression intracellularly and 
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made possible the study of cellular TG2’s effects on metastasis and cancer cell 
properties. But TG2 can also be secreted into the extracellular microenviroment, 
and our group has previously shown that TG2 is detectable in malignant OC 
ascites. The role of TG2 in the extracellular space has not been elucidated, 
particularly as it pertains to cancer progression. Importantly, TG2 functions as an 
enzyme in the extracellular millieu, where Ca2+ concentrations are high and GTP 
concentrations are low. It is therefore possible that the phenotype induced by 
soluble TG2 is dependent on the enzymatioc function of this protein. Examples of 
experiments that will be carried out are in vitro and in vivo assays utilizing 
ovarian cancer cells which do not express TG2 and recombinant purified TG2. 
Effects of soluble TG2 on tumor metastasis in vivo, cell adhesion, cell migration 
and invasion in vitro will be measured. Additionally it will be important to 
understand whether TG2 affects the extracellular matrix through crosslinking and 
transamidation. Effects of soluble TG2 on proliferation and survival of normal 
cells in the matrix (fibroblasts, endothelial cells) will be evaluated. A possibility is 
that TG2 may facilitate the transition of endothelial cells to mesenchymal cells.  
This can be investigated by using similar procedures we used to measure EMT, 
such as morphology of the cells, measurement of markers of differentiation, and 
other functional assays (endothelial tubules formation). 
Lastly, my work has begun dissecting the mechanisms of EMT in ovarian 
cancer by focusing on the effects of TG2 in this process. The observations made 
here can be further extended to better understand E-cadherin expression 
regulation in OC and how this impacts cellular plasticity, as the cancer cells 
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transition between the primary tumor, spheroids in the peritoneal fluid, and 
metastatic sites. This dynamic process is likely to involve context-dependent 
transcriptional regulation for the critical elements that determine cell polarity and 
interaction. By understanding this multi-step process, we can uncover how 
metastasis proceeds and how its critical steps may be intercepted to block 
cancer progression. 
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